INVESTIGATING AUTOPHAGY DYSFUNCTION INDUCED BY A PARKINSON’S
DISEASE-CAUSING MUTATION IN VPS35

by
Abir Ashfakur Rahman

A dissertation
submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy in Biomolecular Sciences
Boise State University

December 2018

© 2018
Abir Ashfakur Rahman
ALL RIGHTS RESERVED

BOISE STATE UNIVERSITY GRADUATE COLLEGE

DEFENSE COMMITTEE AND FINAL READING APPROVALS
of the dissertation submitted by

Abir Ashfakur Rahman

Dissertation Title:

Investigating Autophagy Dysfunction Induced by a Parkinson’s
Disease-Causing Mutation in VPS35

Date of Final Oral Examination:

30 November 2018

The following individuals read and discussed the dissertation submitted by student Abir
Ashfakur Rahman and they evaluated his presentation and response to questions during the
final oral examination. They found that the student passed the final oral examination.
Brad E. Morrison, Ph.D.

Chair, Supervisory Committee

Allan Albig, Ph.D.

Member, Supervisory Committee

Matthew L. Ferguson, Ph.D.

Member, Supervisory Committee

Julia Thom Oxford, Ph.D.

Member, Supervisory Committee

The final reading approval of the dissertation was granted by Brad E. Morrison, Ph.D.,
Chair of the Supervisory Committee. The dissertation was approved by the Graduate
College.

DEDICATION
I would like to dedicate this dissertation to my mother, Lutfa Begum, and my
father, Mujibur Rahman. I hope I have made you proud.

iv

ACKNOWLEDGEMENTS
I would like to thank my thesis advisor, Dr. Brad Morrison, for being the mentor
that he has been and guiding me every step of the way to my doctorate degree. I also
want to thank my committee members, Dr. Allan Albig, Dr. Matt Ferguson and Dr. Julia
Oxford, for providing me with guidance and giving me their valuable time and wisdom. I
would like to extend my special gratitude to Beth Gee (Momma Beth) in the
Biomolecular Sciences Graduate Programs administration, whose help and care has been
priceless in the last four years. The same goes for Raquel Brown, Barb Jibben, Tracy
Yarnell, Diane Smith, Cindy Keller-Peck, Shin Pu and Crystal Scott. Being at the
Biomolecular Research Center was truly an amazing experience. I am grateful to all the
faculty and staff of Department of Biomolecular Sciences, the Biomolecular Research
Center and Department of Biological Sciences at Boise State University for their support
and for giving me a sense of belonging, and for being the amazing human beings that
they are.
I would also like to especially acknowledge the Boise State University Health
Services Center staff members and the Graduate College for being there when I so
desperately needed help. I would like to thank Jennifer Aumeier, LMT, from BSU Health
Services, and Dr. Toby Bingham and the amazing staff members at Life Chiropractic, for
keeping me functional, when it seemed like my body would break apart.
I would like to thank my friend Nabil Rahman for helping me with Adobe
Illustrator. I am also thankful to all the friends I have made here at Boise. I cannot name

v

them all for the sake of space. Last but not least, I could not have done this without my
amazing wife, Rebeka Sultana, my awesome sister, Tasnuva Rahman, my mom, Lutfa
Begum, my dad, Mujibur Rahman and my auntie, Ismat Ara. I love you all and I hope I
have made you proud.

vi

ABSTRACT
Parkinson’s Disease (PD) is an idiopathic disorder with no known cure. With
number of cases steadily rising around the world, it is imperative to turn to the underlying
cellular and molecular mechanisms of the disease manifestation and neurodegeneration to
craft novel modes of therapy. VPS35 is one of the few genes that have identified and
definitively linked to familial PD. The particular mutation that has been associated is
known to cause dysfunction of a key cellular process known as autophagy. This process
is primarily responsible for clearance of unwanted, damaged or misfolded proteins,
among other things. Our study reveals an important link between VPS35, PI3K-AKT
signaling pathway and autophagy dysfunction that might be a potential mechanism of PD
pathogenesis. We also address possible perturbed dopaminergic neurogenesis in the
substantia nigra brain region as a second plausible disease mechanism, as well as a target
for therapeutic intervention.
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CHAPTER ONE: A REVIEW OF THE CONTRIBUTIONS OF VPS35 MUTATIONS
IN PARKINSON’S DISEASE
Parkinson’s Disease (PD) is a multi-system neurodegenerative disease where
approximately 90% of cases are idiopathic. The remaining 10% of the cases can be traced
to a genetic origin and research has largely focused on these associated genes to gain a
better understanding of the molecular and cellular pathogenesis for PD. The gene
encoding vacuolar protein sorting protein 35 (VPS35) has been definitively linked to late
onset familial PD following the identification of a point mutation (D620N) as the causal
agent in a Swiss family. Since its discovery, numerous studies have been undertaken to
characterize the role of VPS35 in cellular processes and efforts have been directed toward
understanding the perturbations caused by the D620N mutation. In this chapter, we
examine what is currently known about VPS35, which has pleiotropic effects, as well as
proposed mechanisms of pathogenesis by the D620N mutation. A brief survey of other
VPS35 polymorphisms is also provided. Lastly, model systems that are being utilized for
these investigations and possible directions for future research are discussed.
Introduction
Parkinson’s disease (PD) is a complex neurological disorder involving both motor
and non-motor symptoms. Affecting 1% of the population over 60, it is the second most
common neurodegenerative disorder (Lau & Breteler, 2006; Williams-Gray et al., 2013).
The prevalence of the disease rises with age. According to a meta-analysis report by
Pringsheim, Jette, Frolkis, & Steeves, (2014), the prevalence is 41 per 100000 between
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ages 40 and 49, rising up to 428 between ages 60 and 69 and 1087 between 70 and 79.
Another report states that there is a greater incidence in men compared to women, at a
ratio of approximately 1.5:1 (Elbaz et al., 2002; K. S. M. Taylor, Cook, & Counsell,
2007; Wooten, Currie, Bovbjerg, Lee, & Patrie, 2004). The case burden in the US alone
is estimated to rise to more than one million by 2030 (Marras et al., 2018).The loss of
motor function occurs primarily due to a loss of dopamine signaling in the basal ganglia.
This loss of dopamine is, in turn, due to the progressive loss of dopaminergic neurons in a
region of the brain known as the substantia nigra. However, it is not only the basal
ganglia that is affected in PD. Research suggests that it involves multiple areas of the
brain and results from a complex interplay between genetic and environmental factors.
Clinically described motor symptoms include resting tremors, bradykinesia, rigidity of
limbs and gait defects. Moreover, there are numerous non-motor symptoms such as
cognitive defects and dementia, mood disorders and sleep disorders that add to the
suffering of the patients (Ascherio & Schwarzschild, 2016; Pringsheim et al., 2014;
Tysnes & Storstein, 2017). According to the centers for disease control and prevention
(CDC), medical complications due to PD rank as the 14th leading cause of death in the
United States (Beard et al., 2017). With no known cure for this disease, research has been
focused on understanding the cellular and molecular processes that may be responsible
for the neurodegeneration.
In terms of neuropathology, some of the hallmarks of PD are the loss of dopamine
producing neurons in the substantia nigra and the formation of toxic protein aggregates in
surviving neurons. Neurofibrillary tangles composed of α-synuclein aggregates formed
structures called Lewy bodies in these neurons. This is also accompanied by

3
mitochondrial dysfunction (Goswami, Joshi, & Singh, 2017). The pathology of the αsynuclein aggregates resembles features of prion disease. This has led to the hypothesis
that α-synuclein has prion properties (Brundin & Melki, 2017; Surmeier, Obeso, &
Halliday, 2017). Some of the genes associated with PD that have been described include
SNCA, LRRK2, VPS35, CHCHD2, GBA, Parkin, PINK1, DJ-1, ATP13A2, FBXO7 and
PLA2G6. These genes have also been reported to disrupt mitochondrial function and
biogenesis (Helley, Pinnell, Sportelli, & Tieu, 2017). Protein homeostasis, particularly
synucleinopathy, and mitochondrial health have therefore become major areas of focus
for research into characterizing PD pathogenesis and developing therapeutics.
Identified VPS35 Mutations
The VPS35 gene was identified by two independent studies in 2011 as linked to
familial PD (Vilariño-Güell et al., 2011; Zimprich et al., 2011). These studies were
conducted using exome sequencing technology on DNA obtained from families that
exhibited evidence of hereditary PD. Subsequent studies have largely concluded that the
D620N mutation is relatively rare, with a calculated prevalence of about 0.115%, from 15
reported case studies involving 21824 PD patients worldwide (Ando et al., 2012;
Blanckenberg, Ntsapi, Carr, & Bardien, 2014; Chen et al., 2013; H Deng et al., 2012;
Hao Deng, Gao, & Jankovic, 2013; Gagliardi, Annesi, Tarantino, Nicoletti, & Quattrone,
2014; Gambardella et al., 2016; Guella et al., 2012; Guo et al., 2012; Gustavsson et al.,
2015; Koschmidder, Mollenhauer, Kasten, Klein, & Lohmann, 2014; Kumar et al., 2012;
Lesage et al., 2012; Shannon et al., 2014; Sharma et al., 2012; Sheerin et al., 2012;
Sudhaman et al., 2013; Y. Zhang et al., 2012). Other polymorphisms in the VPS35 gene
that were identified include L774M, P316S, R524W, I241M, M57I, G51S, R32S, I560T,
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H599R, M607V. However, all of these sequence variations, with the exception of
D620N, have yet to be definitively linked to PD.
In 2005, a study identified VPS35 levels to be reduced in affected brain regions in
Alzheimer’s disease (Small et al., 2005). Another study then reported increased Amyloid
β depositions in mice heterozygous for VPS35 knockout (Vps35+/m) (Wen et al., 2011).
Similarly, other studies have linked abnormal microglial activity and abnormal
hippocampal development, as observed in Alzheimer’s Disease, to VPS35 depletion, but
no polymorphisms in the VPS35 gene have been associated(Appel et al., 2018; C.-L.
Wang et al., 2012).
VPS35 as Part of the Retromer Complex and Related Functions
VPS35 was originally identified in yeast as part of a protein complex called the
retromer complex. This complex is involved in cellular trafficking (M. N. Seaman,
McCaffery, & Emr, 1998). Especially, its role in endosome to Golgi retrograde transport
has been very well characterized (Follett et al., 2014b; Matthew N J Seaman, 2012;
Trousdale & Kim, 2015). Since its identification, retromer dysfunction has been
implicated in Alzheimer’s disease, Parkinson’s disease and several other
neurodegenerative diseases, along with various developmental processes, including wing
and eye development in Drosophila, and bone development (Belenkaya et al., 2008;
Chan et al., 2016; P. Zhang, Wu, Belenkaya, & Lin, 2011). In this context, the interaction
of the retromer complex and the Wnt signaling pathway has been extensively studied
(Belenkaya et al., 2008; Chan et al., 2016; Small & Petsko, 2015; S. Wang & Bellen,
2015; P. Zhang et al., 2011; Q. Zhang et al., 2018). Structurally, VPS35 forms a trimer
with VPS26 and VPS29, to form what is known as the cargo recognition complex (CRC).
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This CRC then associates with a dimer of sorting nexins, belonging to the SNX-BAR
family of proteins. This association is further facilitated by RAB7. Together, the retromer
complex plays important roles in vesicular sorting (Bonifacino & Hurley, 2008; Lucas et
al., 2016; McGough & Cullen, 2011; M. N. J. Seaman, Harbour, Tattersall, Read, &
Bright, 2009; Matthew N J Seaman, 2012). Deficiency of either VPS35 or VPS29 leads
to the degradation of the other two CRC components (Fuse et al., 2015). Transmembrane
receptors such as the cation independent mannose 6 phosphate receptor (CIMPR) and the
membrane iron transporter DMT1 are well characterized targets of retromer mediated
sorting (Arighi, Hartnell, Aguilar, Haft, & Bonifacino, 2004; Lucas et al., 2016; Tabuchi,
Yanatori, Kawai, & Kishi, 2010). In addition, there have been several studies on the role
of the retromer in recycling of beta-2 adrenergic receptors (β2AR) in dendritic cells and
trafficking of G protein coupled receptors (GPCRs) (Bahouth & Nooh, 2017; Bowman,
Shiwarski, & Puthenveedu, 2016; Bunnett & Cottrell, 2010; Choy et al., 2014; Feinstein
et al., 2011; McGarvey et al., 2016; Pavlos & Friedman, 2017; Sposini et al., 2017). The
retromer is known to carry cargo from endosomes to the trans-Golgi network (TGN),
performing retrograde transport, as well as carrying cargo from endosomes to the plasma
membrane, allowing recycling of membrane bound receptors (Trousdale & Kim, 2015).
Moreover, included in the list of retromer cargo, are degradative enzymes such as
Cathepsin D, which are important for lysosomal function and could potentially influence
autophagy. Furthermore, amyloid precursor protein (APP) and α-synuclein (SNCA) are
also reported to be sorted by the retromer complex (Aufschnaiter, Kohler, & Büttner,
2017; Follett et al., 2014b; Follett, Bugarcic, Collins, & Teasdale, 2017; Gallon & Cullen,
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2015; C. Li, Shah, Zhao, & Yang, 2016; Miura et al., 2014; Reitz, 2018). These findings
have sparked considerable interest in the contributions of the retromer to human diseases.
Proposed Mechanisms of VPS35 in Neuronal Dysfunction
The importance of the roles played by the retromer complex in signal transduction
and receptor trafficking points to the dysfunction of the retromer as the major potential
mechanism of neuronal degeneration caused by the VPS35 D620N mutation (Follett et
al., 2014b, 2017; Reitz, 2018; Small & Petsko, 2015; S. Wang & Bellen, 2015). Out of
the three components of the core retromer complex, VPS35-VPS26-VPS29, knockdown
of any one component, except VPS26, leads to the degradation of the other two
components (Fuse et al., 2015). Therefore, given that any free VPS35, existing outside
the retromer complex, is rapidly degraded, the role of VPS35 D620N in PD is likely to
involve altered retromer function. Trafficking defects of AMPA receptors was reported in
a VPS35 heterozygote mouse model as well as cultured mouse hippocampal and cortical
dopaminergic neurons treated with VPS35 shRNA (Munsie et al., 2015; Tian et al.,
2015). Additionally, dopamine receptor D1 (DRD1) is also reported to be recycled with
the involvement of VPS35 (C. Wang et al., 2016).
Studies have reported reduced ⍺-synuclein degradation in VPS35 deficient cells
(Braschi et al., 2010; Miura et al., 2014; Sugiura, McLelland, Fon, & McBride, 2014; F.L. Tang et al., 2015). Formation of toxic ⍺-synuclein aggregates and fibril formation are
hallmarks of PD (Patel & Witt, 2018). This accumulation has been attributed to abnormal
sorting of degradative enzymes that are normally targeted to the lysosome. However, this
accumulation could also be partially due to autophagy defects, which have also been
reported in HeLa cells expressing the VPS35 D620N mutation, attributed to impaired
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WASH (Wiskott–Aldrich syndrome protein and SCAR homolog) complex association
(McGough et al., 2014; Zavodszky et al., 2014). Given that autophagy is a major process
responsible for removing proteins, macromolecules and organelles, this is another
potential mechanism for the neurodegeneration caused by VPS35 (Barth, Glick, &
Macleod, 2010; Lynch-Day, Mao, Wang, Zhao, & Klionsky, 2012; Tofaris, 2012)

Figure 1.1

Cellular processes affected by VPS35 mutations

Furthermore, defects in mitochondrial fusion and function have also been reported
in some studies (Fu-Lei Tang et al., 2015; W. Wang et al., 2016). Mitochondrial
dysfunction has been shown to affect neuronal function severely and is believed to be a
driving force of neurodegeneration (Haelterman et al., 2014; Hauser & Hastings, 2013;
Mullin & Schapira, 2013; Subramaniam & Chesselet, 2013; Winklhofer, 2014). Also, it
is noteworthy that autophagy is the means by which damaged mitochondria are turned
over (Ashrafi & Schwarz, 2013). Therefore, disruption in autophagy due to VPS35

8
D620N mutation may also result in, if not exacerbate, any mitochondrial dysfunction that
may be directed by the VPS35 D620N mutation.
Current Model Organisms and Systems for Studying VPS35
Cell Culture
A variety of tissue culture model systems are available for studying the structure
and function of VPS35, and the pathogenic effects of its mutations. SH-SY5Y
neuroblastoma cells can easily be induced to adopt a dopaminergic state by treatment
with retinoic acid (Korecka et al., 2013; Krishna et al., 2014; Shipley, Mangold, &
Szpara, 2016). This system was used by Tang et al (2015) to demonstrate mitochondrial
impairment due to VPS35 deficiency as well as due to the D620N mutation (Fu-Lei Tang
et al., 2015). This system was also used to characterize the role of VPS35 in lysosomal
clearance of AIMP2, which is a substrate of the PD associated gene, Parkin (Yun et al.,
2017). Microglial BV2 cells have been used in some studies to understand the role of
VPS35 in Alzheimer's Disease, and microglial physiology (Lucin et al., 2013; Yin et al.,
2016). In addition, HEK 293T cells also present a popular choice for understanding
cellular pathways affected by VPS35 and retromer function due to their high plasmid
transfection efficiency (Follett et al., 2014a; Williams et al., 2018; Yang et al., 2008).
McGough et al (2014) used HeLa and RPE-1 cell lines to establish the interaction of
VPS35 and FAM21 of the WASH complex (McGough et al., 2014). Cell lines can
readily be transfected or virally transduced with an siRNA, shRNA or overexpression
vectors to modulate the expression of VPS35 and other genes of interest (Nayerossadat,
Maedeh, & Ali, 2012). Korolchuk et al. (2007) knocked down VPS35 in Drosophila S2
cells using an RNAi approach, in order to identify novel proteins important for
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endocytosis, where candidate proteins were selected based on binding predictions to
either α adaptin or clathrin heavy chain, or on having a predicted membrane bending
domain (such as the BAR domain). These candidate proteins were then knocked down to
screen for subsequent endocytosis defects. VPS35 was among the short list of proteins
that were identified as exhibiting a significant reduction in endocytosis, where the effect
due to VPS35 was the most severe (Korolchuk et al., 2007).
In addition to immortalized cell lines, primary neuronal and glial cultures have
also been used to investigate VPS35 functions and mutations (F.-L. Tang et al., 2015;
Tsika et al., 2014; Wen et al., 2011; Williams et al., 2018). Tang et al (2015) isolated and
cultured dopaminergic neurons from brains of mice expressing microRNA directed
against VPS35 (F.-L. Tang et al., 2015). These cells were found to have a reduced
expression of MFN-2 or Mitofusin, and exhibited mitochondrial fragmentation, as well as
impaired mitochondrial function. Similar results were obtained using SH-SY5Y and NLT
neuroblastoma cultures (Fu-Lei Tang et al., 2015). In the study conducted by Tsika et al
(2014), rat primary cortical cultures were used to show that overexpression of human
VPS35 resulted in neuronal cell death and higher sensitivity to cellular stress like as
reported in PD cases (Tsika et al., 2014). Wen et al (2011) demonstrated using mouse
hippocampal slice cultures that VPS35 haploinsufficiency exacerbates long term
potentiation impairment already present in mice expressing Swedish mutant form of the
amyloid precursor protein (Wen et al., 2011). Williams et al (2018) discovered a novel
link between the PD gene, Parkin, and VPS35, wherein Parkin mediates ubiquitination of
VPS35, which does not affect VPS35 turnover, but may have a role to play in the
retromer mediated endosomal sorting (Williams et al., 2018). Using primary cortical
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neurons, they identified ATG9A, a WASH-dependent retromer cargo, to be missorted
upon silencing of the Parkin gene. Using cell lines and primary cultures can therefore be
very powerful tools for deciphering molecular mechanisms under precisely controlled
conditions.
Mice
Homozygous knockout of VPS35 is embryonically lethal in mice. To overcome
this challenge several mice models have been developed, including a hemizygous
deletion mutant (Wen et al., 2011). This mutant was used to demonstrate that VPS35
interacts with the protease BACE-1, predominantly responsible for Amyloid beta
production, and that VPS35 reduction increases BACE-1 activity in the mouse
hippocampus. In addition, A VPS35 D620N knock-in strain of mice has been developed
recently by Cataldi et al (2018), in collaboration with Jackson Laboratories, to further
characterize dopamine release and monoamine transporters in a VPS35 D620N mutant
background (Cataldi et al., 2018). These mice were generated by Cre-recombinase
mediated recombination of the VPS35 exon 15, on chromosome 8. These mice exhibited
no detectable movement disorders and were similar in locomotion to non-transgenic
mice. However, the dopamine turnover was reported to be increased. Dopamine
transporter levels were reported to have been reduced while vesicular monoamine
transporter levels were increased (Cataldi et al., 2018). Mir and colleagues (2018) used
these same mice to study the interaction between LRRK2 and VPS35 (Mir et al., 2018).
Using this model, they were able to demonstrate that the VPS35 D620N mutation
increases LRRK2 catalyzed phosphorylation of three different RAB proteins, RAB 8a, 10
and 12. They concluded that the VPS35 D620N mutation causes a gain of function with
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respect to the kinase activity of LRRK2 and is an upstream regulator (Mir et al., 2018). A
similar mouse model, generated using a CRISPR/Cas-9 mediated knock-in strategy, was
used previously by Ishizu et al. (2016) to characterize reduced dopamine release in the
striatum of heterozygous mice with one gene copy of VPS35 D620N knocked in
(VPS35D620N KI), while the other copy had one base pair deleted in exon 15, creating a
premature stop codon, referred to as VPS35Del1 (Ishizu et al., 2016). These
VPS35D620NKI/VPS35Del1 heterozygous mice also displayed premature death and
significant neurodegeneration throughout life, indicating that this model could be of
considerable value for Parkinson’s Disease research.
Rat
A transgenic rat model generated via lentivirus mediated gene transfer has been
described and utilized by Tsika et al., (2014). These rats overexpressed one of two human
VPS35 constructs, one of wild type and the other containing the D620N mutation.
However, the researchers concluded that the human D620N construct did not alter
vesicular sorting of retromer cargo proteins in primary cortical neurons from these
animals. They went on to confirm this finding in yeast and human (patient donated)
fibroblasts. Contrary to this finding, the human VPS35 D620N overexpression was found
to induce neurodegeneration in the substantia nigra of these rats suggesting that, in this
model, VPS35 D620N might be primarily causing neuronal loss without altering retromer
function (Tsika et al., 2014).
Drosophila Melanogaster
MacLeod et al (2013) used an overexpression vector to demonstrate that
overexpression of wild type VPS35 reduced the defects caused by LRRK2 G2019S
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mutation, and those caused by RAB7L1 knockdown. This was shown in LRRK2 mutant
flies and primary rat neuronal cultures (MacLeod et al., 2013). Similarly, a VPS35
overexpressing strain of flies was used by Linhart et al in 2014, to demonstrate the rescue
of LRRK mutation derived eye defects, by eye specific VPS35 overexpression in
Drosophila (Linhart et al., 2014), obtained from the Bloomington Drosophila Stock
Center. In another study, flies with the Drosophila VPS35 (dVps35) knocked out, were
shown to be embryonically lethal (Inoshita et al., 2017). This lethality could not be
rescued by knock-in of human VPS35 wild type or human VPS35 D620N. However, it
was rescued by knock-in of dVps35 WT and by knocking in dVps35 D647N (the
Drosophila analog of the D620N mutation in humans). Using transgenic flies expressing
wild type dVps35 or dVps35 D647N, in all three possible dVps35 heterozygote and
homozygote backgrounds (+/+, +/-, -/-), they were then able to demonstrate that
Drosophila LRRK (dLRRK) and dVps35 affect synaptic architecture and endocytosis via
the same pathways (Inoshita et al., 2017).
Saccharomyces Cerevisiae and Caenorhabditis Elegans
Dhungel et al (2015) discovered that in VPS35 deficient yeast cells, EIF4G1
upregulation was highly toxic, but the two mutations by themselves were not lethal
(Dhungel et al., 2015). EIF4G1 is a translation initiation factor scaffold protein,
responsible for the translation initiation complex formation (Villa, Do, Hershey, &
Fraser, 2013). While they could not establish a direct interaction between the two
proteins, a few common pathways were identified leading to the hypothesis that they
were functionally related. The authors also noted that in a VPS35 null background,
overexpression of EIF4G1 resulted in fewer but larger synaptic boutons. This group then
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investigated proteotoxic stress in yeast cells and activation of the unfolded protein
response (UPR). It was seen that there was increased proteotoxic stress and UPR
activation in VPS35 deletion mutants, only upon overexpressing EIF4G1. This led to the
conclusion that the EIF4G1 upregulation combined with retromer dysfunction was
causing toxic protein aggregation. In addition, they demonstrated that Sortillin functions
downstream of VPS35 or in parallel and is able to suppress the EIF4G1 overexpression
toxicity in VPS35 deletion mutants. Lastly, this group showed, using yeast, C. elegans
and transgenic mice that VPS35 deletion increases alpha synuclein driven toxicity. In
transgenic mice, increased toxicity was also seen after overexpression of VPS35 D620N
and VPS35 P316S (Dhungel et al., 2015). Therefore, altered VPS35 function can
facilitate protein aggregation, a hallmark of PD.
Future Research Directions
With the advent of CRISPR/Cas-9 mediated genome editing technology,
therapeutic applications targeting the VPS35 gene can now be conceived (Calatayud,
Carola, Consiglio, & Raya, 2017). This could potentially be done in inducible pluripotent
stem cells, obtained from patients, genetically modified and transplanted into the affected
individuals’ brains. This technique has recently been described and is awaiting U.S Food
and Drug Administration approval (Loring, 2018). A major obstacle in such an approach
is the prion like properties of α-synuclein aggregates (Brundin & Melki, 2017). The preexisting toxic α-synuclein aggregates in the patient’s existing brain environment may
induce the formation of α-synuclein fibrils in the transplanted cells, thus negating any
corrections made in the genome. Similar outcome was observed in patients who received
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embryonically derived grafting (Kordower, Chu, Hauser, Freeman, & Olanow, 2008; J.Y. Li et al., 2008).
In addition, further characterization of the VPS35 D620N knock-in mice is now
required to properly investigate the cellular pathways that are perturbed. With this in vivo
model system, work done with in vitro settings must now be validated. Furthermore, a
cell line containing the D620N mutation in the endogenous VPS35 gene would add
validity to findings already reported using cells that have a VPS35 D620N construct
stably overexpressed. Finally, characterization of the pathways perturbed by mutations in
VPS35, is far from complete. A better understanding of the interplay of VPS35 and these
pathways is required, so that therapeutic interventions can be crafted.
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CHAPTER TWO: ENHANCED HYALURONAN SIGNALING AND AUTOPHAGY
DYSFUNCTION BY VPS35 D620N
The motor features of Parkinson’s disease result from loss of dopaminergic (DA)
neurons in the substantia nigra with autophagy dysfunction being closely linked to this
disease. A PD-causing mutation in VPS35 (D620N) has been reported to block
autophagy. In order to identify signaling pathways responsible for this autophagy defect,
we performed an unbiased screen using RNA sequencing (RNA-Seq) of wild-type or
VPS35 D620N-expressing retinoic acid-differentiated SH-SY5Y cells. We report that
VPS35 D620N-expressing cells exhibit transcriptome changes indicative of alterations in
extracellular matrix (ECM)-receptor interaction as well as PI3K-AKT signaling, a
pathway known to regulate autophagy. Hyaluronan (HA) is a major component of brain
ECM and signals via the ECM receptors CD44, a top RNA-Seq hit, and RHAMM to the
autophagy-regulating PI3K-AKT pathway. We find that high (>950 kDa), but not low
(15 - 40 kDa), molecular weight HA itself can inhibit autophagy. In addition, VPS35
D620N facilitated enhanced HA-AKT signaling. Transcriptomic assessment and
validation of protein levels identified the differential expression of CD44 and RHAMM
isoforms in VPS35 D620N mutant cells. Based upon this expression profile, these data
suggest that the RHAMM isoform V3 may contribute to the enhanced activation of HAAKT signaling and autophagy inhibition by VPS35 D620N.
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Introduction
PD is a Progressive Neurodegenerative Disease
In the USA, with a prevalence of 1% in people over 60 and over 4% by age 85,
Parkinson’s disease is the most common disease of motor system degeneration (Lau &
Breteler, 2006). This disease is clinically characterized by a resting tremor, rigidity,
postural instability, and bradykinesia. PD’s primary motor features result from a loss of
dopaminergic (DA) neurons in the substantia nigra pars compacta (SN) region of the
midbrain. Specifically, the loss of dopamine produced by this neuronal subset causes
dysfunction of the basal ganglia, a cluster of nuclei responsible for coordinating
movement. No therapies to date deal with the underlying neuronal loss and thus only
symptomatic treatments exist for PD (Jankovic & Stacy, 2007).
Autophagy Misregulation in PD
Macroautophagy (hereafter referred to as autophagy) is an orderly process of
cytoplasmic engulfment by lipid membrane-bound vesicles termed autophagosomes
leading to degradation of the encapsulated material (La Spada & Taylor, 2010).
Autophagy proceeds in distinct steps that include induction, cargo recognition,
autophagosome formation and transport, autophagosome-lysosome fusion, degradation of
cargo, and the release of degraded material into the cytoplasm. Following the induction
of autophagy, Atg8 (LC3) undergoes cleavage, and a Phosphatidylethanolamine(PE)
moiety is conjugated (now LC3-II). LC3-II is unique to autophagosomes and is
commonly used as a marker for autophagy (He & Klionsky, 2009). Autophagosomes fuse
with endosomes and multivesicular bodies that in turn fuse with lysosomes containing
lytic enzymes that facilitate the degradation of cargo.
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Autophagy is primarily devoted to adapting to nutrient limitation, degrading
misfolded proteins, and removing dysfunctional organelles (A. M. K. Choi, Ryter, &
Levine, 2013). Studies of neurodegenerative disease and protein turnover pathways have
indicated that the maintenance of protein quality control presents a particular challenge
for neurons and other specialized cells of the nervous system (Malgaroli, Vallar, &
Zimarino, 2006; J. P. Taylor, Hardy, & Fischbeck, 2002). This appears to be of particular
importance to PD pathology as protein aggregates of α-synuclein are believed to be
removed by autophagy, at least before fibril formation, and whose presence may signal
autophagy dysfunction (Riedel, Goldbaum, Schwarz, Schmitt, & Richter-Landsberg,
2010; Tanik, Schultheiss, Volpicelli-Daley, Brunden, & Lee, 2013). Moreover,
inflammation and other proteotoxic insults can facilitate α-synuclein aggregation, perhaps
by overloading the autophagic machinery with damaged proteins and organelles or by
inhibiting autophagy directly. A link between PD and autophagy can also be traced
genetically. For example, at least seven monogenic causes of PD strongly connected with
autophagy regulation exist, and some are directly involved in lysosomal biology (Dehay
et al., 2010, 2013). As a result, considerable effort has been made to understand
autophagy dysfunction in PD, with the goal of targeting this process for therapy.
The PD-Causing VPS35 D620N Mutation Affects Retromer Function and Blocks
Autophagy
In 2011, two independent groups reported the mutation of VPS35 (D620N) as
being causal for a familial form of PD (Vilariño-Güell et al., 2011; Zimprich et al., 2011).
VPS35 has a well-established and critical role in retromer function. The retromer is a
highly conserved complex of proteins and an essential element of the endosomal sorting
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machinery that directs the recycling of plasma membrane receptors. The retromer is
comprised of a cargo recognition trimer containing VPS35-VPS29-VPS26 and a dimer
made of an assortment of SNX1, SNX2, SNX5, and SNX6 (McGough & Cullen, 2011).
This complex associates with endosomes and facilitates the retrograde transport of
transmembrane cargo to the trans-Golgi network, thereby rescuing cargo from
degradation by the lysosome. However, the mechanism for VPS35 D620N-mediated
neurodegeneration remains unknown.
Interest into the role of VPS35 in mediating autophagy was initially hinted at in
work published by Dengjel et al where VPS35 was identified in an autophagosomeinteractor screen (Dengjel et al., 2012). Subsequently, Zavodszky et al., presented direct
evidence of this by reporting that the PD-causing VPS35 D620N mutation impairs
autophagy in HeLa cells through defective WASH complex recruitment to endosomes
(Zavodszky et al., 2014). However, the study by Zavodszky et al. focused on members of
the WASH complex—namely, canonical interactors of VPS35 (Gomez & Billadeau,
2009; Hao et al., 2013). Interestingly, we did not detect an association with the principal
WASH complex member WASH1 in retinoic acid (RA)-differentiated SH-SY5Y cells, a
widely used cellular model of PD (Korecka et al., 2013; Krishna et al., 2014), suggesting
the existence of distinct mechanism (Fig. S1). Therefore, we performed an unbiased
transcriptome screen of RA-differentiated SH-SY5Y cells that we engineered to stably
express VPS35 or VPS35 D620N using RNA sequencing. Our analysis has uncovered
altered signaling in PI3K-AKT and extracellular matrix (ECM)-receptor interaction
pathways.
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Autophagy Regulation by Phosphatidylinositol-AKT Signaling
Autophagy is regulated by two distinct kinase complexes: an autophagy-specific
phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR)
(Janku, McConkey, Hong, & Kurzrock, 2011). Members of the PI3K family
phosphorylate phosphatidylinositol (PI) generating phosphatidylinositol 3-phosphate
(PI3P) which serves as a docking lipid that can facilitate the complex formation and
activation of proteins that include AKT. AKT then propagates this signal through a series
of kinase events that result in suppression of autophagy. Our transcriptome screen
revealed this pathway as a top hit affected by VPS35 D620N, suggesting it could be a
major effector for autophagy blockade.
HA-AKT Signaling
The major structural component of brain extracellular matrix (ECM) is
hyaluronan (HA), which not only serves as the main anchoring point for brain cells but is
also an important facilitator of intracellular signaling. CD44 and RHAMM are primary
receptors for HA that signal to AKT upon binding (Lin, Chang, & Ying, 2007; Onodera,
Teramura, Takehara, & Fukuda, 2015; Trapasso & Allegra, 2012, p. 44). Our RNA-Seq
data indicates that VPS35 D620N causes altered extracellular matrix receptor interaction
and suggests dysregulated PI3K-AKT signaling. Interestingly, while studies have been
reported showing HA, CD44 and RHAMM activation of the autophagy modulators AKT
and mTOR there are no reports directly addressing HA regulation of autophagy. We then
hypothesized that perturbed HA-AKT signaling may contribute to VPS35 D620N
autophagy dysfunction.
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Results
VPS35 D620N Inhibits Autophagy
To determine whether VPS35 D620N represses autophagy in a PD model system,
we first engineered a human neuroblastoma cell line (SH-SY5Y) to stably express WT or
D620N VPS35 (V5–tagged). This was done by obtaining a VPS35-expressing lentivirus
construct from Lynda Chin (Scott et al., 2009) and generating the D620N mutation by
site-directed mutagenesis. We next infected low passage SH-SY5Y cells (ATCC) and
selected transgene-positive cells using blasticidin. Before conducting experiments, we
differentiated SH-SY5Y cultures into post mitotic dopaminergic neuron-like cells using
10uM retinoic acid for 7 days. Western blot revealed that WT and D620N transgenic
proteins are expressed equally and at a similar level to endogenous VPS35 (Fig. 2.1A). In
stable cell lines, no endogenous VPS35—only transgenic (shifted) VPS35—was
detected, which is likely due to transgenic VPS35 titrating out endogenous VPS35 from
the retromer complex. The knockdown of VPS35 results in the knockdown of the other
core retromer component members (VPS29) and vice versa, suggesting that free VPS35
as well as VPS29 are rapidly degraded by the cell (Fig. 2.2C) (Fuse et al., 2015).
Therefore, serendipitously, these cell lines express the transgene at endogenous protein
levels, thereby avoiding overexpression artifacts. Upon examination of autophagy in
these cells, we found autophagy to be robustly inhibited by D620N, as evidenced by the
reduced LC3-II induction following Bafilomycin A1 treatment (Figs. 2.1B and 2.1C).
We further tested autophagy dysfunction by VPS35 D620N through assessing the
clearance of intracellular alpha-synuclein aggregates (Fig. S2) (Outeiro et al., 2008). We
report that mutant-expressing cells accumulated significantly higher levels of alpha-
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synuclein aggregates which supports the notion that VPS35 D620N is a potent inhibitor
of autophagy.

Figure 2.1

VPS35 D620N inhibits autophagy.

Transgenic and endogenous VPS35 were evaluated using western blot (A). Differentiated
SH-SY5Y cells stably expressing transgenic VPS35 (WT or D620N) were treated with
Baf A1 to block autophagosome/lysosome fusion. Western blot of LC3-II was performed
(B) and autophagic flux quantified (C). Results from three independent experiments are
displayed (*P<0.05 compared to indicated group, student’s t-test; error bars = SEM).
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Figure 2.2

VPS35 knockdown inhibits autophagy.

VPS35 expression was knocked down in differentiated SH-SY5Y cells neurons by two
distinct lentivirus-delivered shRNA vectors. Following selection with puromycin, cells
were treated with Baf A1 to block autophagosome/lysosome fusion. Western blot of
LC3-II was performed (A) and autophagic flux quantified (B). Results from three
independent experiments are shown (*P<0.05 versus indicated group, student’s t-test;
Error bars = SEM). Knockdown of VPS29 by shRNA using a lentiviral vector was also
performed (C).

VPS35 Knockdown Inhibits Autophagy, Phenocopying the VPS35 D620N Mutation.
To determine if the D620N mutation elicited autophagy blockade through a loss
of function in differentiated SH-SY5Y cells, we knocked down VPS35 expression using
two distinct shRNA constructs delivered by lentivirus and assessed autophagy (Fig. 2.2A
and B). We found that VPS35 knockdown resulted in repression of autophagy consistent
with VPS35 D620N being a loss-of-function mutation. As reported by other groups, we
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found that knockdown of other core retromer components such as VPS29 by shRNA
resulted in concomitant knockdown of VPS35 (Fig. 2.2C) (Fuse et al., 2015). Therefore,
it was not surprising to observe that VPS29 knockdown also suppressed autophagy.
Collectively, these data suggested that VPS35 D620N is a loss-of-function mutation,
which ultimately suppresses autophagic activity.
VPS35 D620N Misregulates ECM-Receptor Interaction and Pi3k-AKT Pathway Gene
Expression
Having established autophagy dysfunction by VPS35 D620N, likely through a
loss-of-function, we next sought to determine a precise molecular mechanism for this
phenomenon. To this end, we performed RNA sequencing of the transcriptomes of
transgenic WT and D620N VPS35-expressing SH-SY5Y cells. Gene ontology was
performed (1.5 fold change cutoff) using iPathways (Advaita) and KEGG annotated
pathways were assigned to gene expression changes (Luo, Friedman, Shedden,
Hankenson, & Woolf, 2009; Mootha et al., 2003; Subramanian et al., 2005). Top pathway
hits were ECM-receptor interaction and PI3K-AKT signaling which suggests that ECM
signaling is perturbed by VPS35 D620N (Table 1). Examination of specific transcripts
altered for ECM-receptor interaction and PI3K-AKT KEGG annotated pathways reveals
that CD44 mRNA expression is misregulated in VPS35 D620N cells (Fig. 2.3).

24
Table 2.1.
D620N.

ECM-receptor interaction and AKT pathway perturbation by VPS35

RNA-Seq was performed on WT and VPS35 D620N-expressing SH-SY5Y cells. The top
5 pathways affected by VPS35 D620N expression and relevant significance values are
listed.
Pathway name

Pathway
ID

p-value

p-value
(FDR)

p-value
(Bonferroni)

Pathways in cancer

05200

9.878e-8

2.683e-5

2.914e-5

Systemic lupus
erythematosus

05322

1.819e-7

2.683e-5

5.367e-5

ECM-receptor
interaction

04512

2.294e-6

2.256e-4

6.768e-4

PI3K-AKT signaling
pathway

04151

3.124e-6

2.304e-4

9.215e-4

Focal adhesion

04510

9.627e-6

5.680e-4

0.003
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Figure 2.3.

Transcriptome alteration of ECM-receptor and PI3K-AKT pathways
by VPS35 D620N.

Specific transcript expression changes (Log-Fold-Change) for ECM-receptor interaction
(Top) and PI3K-AKT signaling (Bottom) KEGG pathways from RNA-Seq data are
shown. The distribution of all gene perturbations in the pathway are represented in the
box plot where the first, median and third quartile are indicated.
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Hyaluronan Inhibits Autophagy in Differentiated SH-SY5Y Cells
Our findings from RNA-Seq data indicate that HA-AKT signaling is perturbed in
the VPS35 mutant cell line. These results pose the novel question of whether the HAAKT signaling axis controls autophagic response. To test this directly, we added HA at
concentrations reported to elicit biological effects in human monocytes and fibroblasts to
differentiated SH-SY5Y cells (Maharjan, Pilling, & Gomer, 2011). We chose to treat
cells with either high (HMW) or low molecular weight (LMW) HA since the polymer
size can direct divergent bioactivities (Maharjan et al., 2011). We observed a dosedependent repression of autophagy following treatment with HMW but not LMW HA
(Fig. 2.4). This is the first report of HA modulating autophagy and may indicate that the
composition of ECM is an important factor in the regulation of this key process.
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Figure 2.4.

HA inhibits autophagy.

RA-differentiated SH-SY5Y cells were treated with high molecular weight (>950 kDa)
HA in serum-free media for 24 hours. The next day, cells were treated with or without
Baf A1 and autophagic flux assessed by LC3-II/β-Actin western blot (A) and quantified
from three experiments (B). Similarly, low molecular weight (15 - 40 kDa) HA treatment
was performed and autophagic response evaluated by LC3-II/β-Actin western blot (C)
and represented graphically (D) (*P<0.05 versus indicated group, student’s t-test; Error
bars = SEM).
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Altered Hyaluronan-AKT Signaling by VPS35 D620N
We next examined whether VPS35 D620N-expressing cells exhibited heightened
sensitivity to HA. Addition of HMW HA resulted in elevated AKT activation in mutant
cells (Fig. 2.5A). Conversely, low molecular weight HA failed to induce AKT activation
in either WT or mutant cells (Fig. 2.5B). This suggests that VPS35 D620N facilitates
enhanced HMW HA signaling. These results are also consistent with our findings that
HMW and not LMW HA repress autophagy via canonical HA-AKT signaling.

Figure 2.5.

Elevated HA signaling by VPS35 D620N.

Differentiated SH-SY5Y cells expressing wild-type (WT) or D620N VPS35 were serumdeprived overnight. The following day, high molecular weight (>950 kDa) HA (300
ug/mL) (A) or low molecular weight (15 - 40 kDa) HA (300 ug/mL) (C) was added for
the indicated times and western blotting was then performed (p-AKT = Ser473). Results
are presented as a ratio of D620N/WT for p-AKT/β-Actin by western blot band
densitometry for each time point shown (B, D) (*P<0.05 versus indicated group,
student’s t-test; Error bars = SEM).
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AKT Pathway Activation by VPS35 D620N is Independent of Hyaluronan Production
To determine whether HA production contributes to heightened AKT signaling in
VPS35-D620N cells, we measured HA produced during a 48h period (Fig. 2.6), but
found no detectable difference in wild-type and mutant cells. We also assessed the
protein levels for the hyaluronan synthase (HAS) enzymes responsible for HA synthesis.
HAS3 was not differentially expressed while we were unable to detect HAS1 and HAS2
in SH-SY5Y cells (Fig. 2.7A). Taken together, these findings suggest that enhanced HA
production is not responsible for the observed change in AKT signaling for VPS35
D620N-expressing cells.

Figure 2.6.

VPS35 D620N does not affect HA production.

ELISA detection of HA (all forms, >35kDa) production in cell culture supernatant (over
48h in 0.5% FBS-containing media) from differentiated wild-type and mutant SH-SY5Y
cells (results from three independent experiments; student’s t-test; P>0.05; Error bars =
SEM).
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Figure 2.7.

VPS35 D620N alters CD44 and RHAMM protein expression.

Western blot of differentiated SH-SY5Y cells expressing wild-type (WT) or D620N
VPS35. Visualization of CD44 protein required 60-80ug total lysate and ECL Plus
reagent (A). RHAMM protein detection was done using 10ug of total lysate and standard
ECL reagent (B).

Misregulated CD44 and RHAMM Expression by VPS35 D620N
Our RNA Seq analysis revealed that ECM-receptor interaction pathways were a
top hit for VPS35 D620N-expressing cells (Table 2.1). From this dataset we also found
that CD44 transcript expression increased significantly in VPS35 D620N-expressing
cells. Consistent with CD44 pathway misregulation, assessment of protein expression
revealed heightened CD44 expression in the mutant cells (Fig. 2.7A). Interestingly, only
a single truncated isoform of CD44 protein was observed that correlated to CD44v4.
Identity of CD44v4 was confirmed by further analysis of the RNA Seq data. What’s
more, CD44v4 was very lowly expressed at both the protein level, requiring 60-80ug of
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total lysate and a sensitive ECL reagent (WesternSure) to detect, and RNA level, nearing
the limit of accurate detection in our RNA-Seq dataset (Table 2.2). These factors led us
to speculate that CD44 likely provides only a minor contribution to HA signaling in SHSY5Y cells. We then examined the protein levels of RHAMM, another primary receptor
for HA, and found robust expression of multiple isoforms. However, RHAMM isoform 3
(RHAMMv3) protein was strikingly absent from VPS35 D620N-expressing cells (Fig.
2.7B). The identities of all four NCBI annotated isoforms were confirmed at the
transcript level by RNA-Seq data. Collectively, these data suggest that the RHAMMv3
may contribute to the enhanced activation of HA-AKT signaling and autophagy
inhibition by VPS35 D620N mutation, with minor contributions from CD44
misregulation.
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Table 2.2.
expression.

VPS35 D620N affects CD44 and RHAMM RNA splice variant

SpliceR program analysis was performed on the WT and VPS35 D620N RNA-Seq
dataset. Relative expression profiles are presented for all NCBI annotated splice variants
as a function of FPKM for CD44 (A) and RHAMM (B). Significance for differential
expression by WT versus D620N is shown.
(A)
Isoform

Ref. Seq.

Rel. Exp.

Rel. Exp.

WT/D620N

WT

D620N

Ratio

p-value

V1

NM_000610

0.0000

0.0000

INF

1

V2

NM_001001389

0.0000

0.0142

0

1

V3

NM_001001390

0.0000

0.0000

INF

1

V4

NM_001001391

0.3387

1.0256

0.3303

0.0452

V5

NM_001001392

0.1853

0.0000

INF

1

V6

NM_001202555

0.0000

0.0256

0

1

V7

NM_001202556

0.0000

0.0004

0.0954

1

V8

NM_001202557

0.0444

0.0000

INF

1

Ref. Seq.

Rel. Exp.

Rel. Exp.

WT/D620N

p-value

WT

D620N

Ratio

(B)
Isoform

V1

NM_001142556.1

5.1525

5.5884

0.9220

0.6159

V2

NM_012484.2

0.9834

0.3711

2.6500

0.3170

V3

NM_012485.2

13.5848

13.0535

1.0407

0.6639

V4

NM_001142557.1

1.4806

0.6353

2.3306

0.2983
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Discussion
The study of monogenic causes of PD has yielded valuable insights into the
pathogenesis of this disease. The identification of VPS35 D620N as a causal familial
factor has allowed for the molecular dissection of signaling pathways that could be
important therapeutic points for this and other forms of PD. It is well-established that
VPS35 D620N inhibits autophagy and that this mutation also hinders retromer function
(Follett et al., 2014b; McGough et al., 2014; Zavodszky et al., 2014). Accordingly,
research focus in the field has been placed upon canonical retromer interactors and
pathways. This approach might be limiting as our group’s inability to confirm WASH
complex-retromer interaction in SH-SY5Y cells suggests. Therefore, in an effort to assay
all potentially relevant signaling pathways we have created isogenic transgenic SH-SY5Y
cell lines expressing VPS35 or VPS35 D620N and performed RNA Seq transcriptome
analysis.
Identification of perturbed HA-AKT signaling as a contributor to VPS35 D620Nmediated autophagy dysfunction may offer a therapeutic target for PD as well as broaden
the understanding of autophagy regulation. We report for the first time to the authors’
best knowledge that HMW HA serves as a negative regulator of autophagy. Given the
high concentration of HMW HA in the mammalian brain, the physiological consequences
of this finding could be far-reaching. In the scope of neurological disease, defective
autophagy is linked to a wide variety of maladies (Levine & Kroemer, 2008). If HMW
HA and autophagic activity are coupled, then one could imagine that the concentration
and quality of HMW HA might guide the path of neurodegenerative disease particularly
as we age and are less adept at maintaining ECM. In the context of PD, recognition of
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HA-AKT pathway involvement in the misregulation of autophagy in catecholaminergic
cells could provide a novel target for treatment.
Our discovery that VPS35 D620N-expressing cells have heightened response to
HMW but not LMW HA indicates that HA-AKT signaling is not initiated by a traditional
ligand-receptor mechanism. This finding would imply that the responsible HA receptor(s)
require scaffolding to a large ECM structure for activation. Previous work has indeed
shown that cytoarchitecture is important for HA signaling (Neame, Uff, Sheikh,
Wheatley, & Isacke, 1995). Maharjan and colleagues have specifically explored the
signaling divergences between HMW and LMW HA (Maharjan et al., 2011). During
remodeling, such as following injury, HMW HA is broken down to LMW by matrix
metalloproteinases (MMP). This group reported that environments can direct monocyte
differentiation and activation based upon HA polymer size. It is therefore not
inconceivable that brain HA composition could serve a similarly important function.
CD44 and RHAMM are the most researched HA receptors. These proteins have
largely been studied in the context of cancer metastasis due to being refined sensors for
detecting the state of ECM for an invading cancer cell (Savani et al., 2001, p. 44). Upon
identifying defective HA-AKT signaling we examined CD44 and RHAMM expression.
We report that SH-SY5Y cells express only a single isoform (V4) of CD44 (CD44v4)
protein, albeit at very low levels, and that this isoform is found in higher amounts in
mutant versus control cells. We also found that CD44v4 protein and mRNA levels
correlate closely. However, the extremely low level of CD44 expression coupled with the
observation that the CD44 protein expression is likely controlled largely by
transcriptional mechanisms suggest that CD44 plays a minor role in VPS35 D620N
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dysfunction. In contrast, RHAMM protein is abundantly expressed yet isoform V3
(RHAMMv3) is strikingly absent from VPS35 D620N-expressing cells. Interestingly,
RHAMMv3 transcript levels are indistinguishable for the wild-type and mutant cells
indicating post-splicing regulation of expression and potentially a direct role for VPS35.
Taken together, these data suggest that the RHAMMv3 may contribute to the enhanced
activation of HA-AKT signaling and autophagy inhibition by VPS35 D620N.
The receptor for hyaluronan-mediated motility, RHAMM, is expressed on the cell
surface as well as intracellularly. RHAMM was shown to associate with cytoskeletal
components (Assmann, Jenkinson, Marshall, & Hart, 1999) in addition to the mitotic
spindle (Christopher A. Maxwell et al., 2003) and direct numerous processes including
mitosis and tumorigenesis (Christopher Alan Maxwell, McCarthy, & Turley, 2008;
Mohapatra, Yang, Wright, Turley, & Greenberg, 1996). Thus, the study of this protein
has been of particular interest in the context of cancer. Interestingly, Sohr et. al.
demonstrated that overexpression of a tumor suppressor p53 mutant that lacks DNAbinding ability results in a specific loss of the RHAMMv3 isoform in DLD-1 cells (Sohr
& Engeland, 2008). This group and others have also shown that p53 regulates
transcription of the RHAMM gene (Schütze et al., 2016; Sohr & Engeland, 2008).
Specific functionality of RHAMMv3 is also suggested from clinical data indicating that
the RHAMMv3:RHAMMv1/v2 ratio is associated with a poor prognosis for multiple
myeloma (Christopher A. Maxwell et al., 2004) and non-small cell lung carcinoma (D.
Wang et al., 2016). It is important to note that RA-differentiated SH-SY5Y cells are postmitotic so aberrant p53 activity would result from genomic instability or inappropriate
signaling that is not a direct result of the cell cycle. Our RNA Seq data reveals cancer
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signaling through focal adhesion or growth factor receptors as the top overall hit for
altered signaling by VPS35 D620N. It is therefore not unreasonable to hypothesize that
this perturbed signaling mediated by VPS35 D620N affects p53 activity which might inturn lead to repression of RHAMMv3 expression. Further investigation into a HARHAMM-p53-VPS35 signaling axis could provide valuable insights into PD and cancer.
In summary, we report that VPS35 D620N suppresses autophagy in RAdifferentiated SH-SY5Y cells in a manner consistent with a loss of function mutation.
Using an unbiased RNA Seq screen, we identified misregulated ECM-receptor and PI3KAKT signaling pathways in the mutant cells. Subsequent investigation revealed enhanced
HMW HA-AKT signaling with an expression defect in a single isoform of RHAMM
(RHAMMv3) being a likely contributing factor. These results provide a compelling
rationale to further investigate ECM dynamics in PD and other neurological disorders.
Methods
Tissue Culture
SH-SY5Y human neuroblastoma cells (ATCC) were cultured in T175 tissue
culture flasks and maintained at 37°C with 5% CO2 environment. Cells were cultured in
DMEM/F12 50/50 media (Corning) with L-glutamine, 15% Fetal Bovine Serum (Atlanta
Biologicals), 1% non-essential amino acids, 1% penicillin/streptomycin solution
(Hyclone, 10000 units/mL Penicillin/10000µg/mL Streptomycin). Cells were passaged
when flasks reached ~80% confluency using 0.25% Trypsin, with 2.2mM EDTA and
sodium bicarbonate (Corning). Cells at passage numbers 8 thru 15 were used for
experiments. For this, cells were plated on multi-well tissue culture plates at the
necessary cell concentrations (e.g., 4 million cells per well on a 6-well plate). Prior to
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experimentation, the cells were treated with retinoic acid for 7 days, to differentiate them
into post-mitotic catecholaminergic neuron-like cells. Transgenic cells were also treated
72h prior to experimentation with 2mM sodium butyrate to reactivate transgene
expression (K. H. Choi, Basma, Singh, & Cheng, 2005). 293TA cells were grown in
DMEM media with 1.0 g/L Glucose, with L-glutamine and with Sodium Pyruvate
(VWR), supplemented with 10% Fetal Bovine Serum (Atlanta Biologicals), 1% nonessential amino acids (Corning Cellgro) and 1% penicillin/streptomycin solution
(Hyclone, 10000 units/mL Penicillin/10000µg/mL Streptomycin).
Western Blotting
Life Technologies Bolt gels and reagents were used for western blotting. Cells
were lysed using RIPA lysis buffer containing a protease inhibitor cocktail and then
sonicated. This was then followed by centrifugation at 15000g for 10 minutes and
collecting supernatant. Total protein levels were measured and normalized across
samples. Polyacrylamide gel electrophoresis was performed on the protein extracts
followed by transfer onto a PVDF membrane. Transfers to PVDF membranes were
performed using the iBlot2 Dry Transfer device (Life Technologies). Primary antibodies
were used to detect LC3 (Novus Biologicals, NB100-2220), CD44 (Origene, TA506726),
Phospho-AKT (Ser 473) (Cell Signaling, 4060), RHAMM (Genetex, GTX54121) and βactin (Thermo Fisher, MA1-91399). Secondary antibodies (anti-mouse, Cell Signaling,
7076; anti-rabbit, Cell Signaling, 7074) were used for probing PVDF membranes after
primary antibody incubation. ECL substrate (Pierce, 32106) or, for more sensitive
detection, WesternSure chemiluminescent substrate (LI-COR, 926-95000) was then used
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to visualize protein bands and images obtained with a ChemiDoc Touch Gel Imager
(BioRad). Protein expression was quantified by densitometry using Image J (NIH).
Lentivirus Production and Transduction
Life Technologies Virapower lentiviral production kit was used to generate
lentivirus. 293TA cells (GeneCopoeia) were transfected with plasmids using
Lipofectamine 2000 (Life Technologies). Media was replaced the next day. The
supernatant media containing active, fully assembled lentiviruses, was collected 48 hours
after transfection and filtered through 400 nm pore filters, aliquoted and stored at -80°C
until use. For transduction of SH-SY5Y cells, virus containing supernatant was added
directly to the culture media. This media was replaced the next day and antibiotic
selection (blasticidin or puromycin) for transduced cells was initiated 72 hours following
viral supernatant addition.
Autophagic Flux Assay
Bafilomycin A1 (100nM) was used to block autophagy in experimental cells, four
hours prior to lysis. This was then followed by comparison of LC3-II levels normalized
to β-Actin between bafilomycin A1 treated and untreated cells obtained from western blot
imaging as previously described (Klionsky et al., 2012).
Hyaluronan Treatment
Cells were plated at a density of 4 million cells per well on 6 well plates. Cells
were then differentiated with RA for 7 days. On the day prior to lysis, cells were treated
with high or low molecular weight HA in serum-free media and then lysed using RIPA
lysis buffer, as described above. For autophagic flux assays, cells were treated with or
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without HA in the presence or absence of Bafilomycin A1 (100nM) for 4 hours
immediately prior to lysis and then autophagic flux assessed as described above.
Hyaluronan Quantification
ELISA measurement of Hyaluronan was performed using a Quantikine ELISA kit
(R&D Systems, DHYAL0) according to the manufacturer’s instructions. Briefly, cells
were plated on 96 well plates at 50,000 cells/well. The cells were then treated with
retinoic acid media for seven days. After differentiation, the media was replaced with
growth media containing 0.5% FBS and RA. Supernatant was then collected after 48
hours for ELISA analysis. It should be noted that this ELISA system detects all forms of
HA (>35kDa).
Differential Gene Expression, Splicing and Gene Set Enrichment Analysis
Transgenic WT and VPS35 D620N-expressing cells grown in 100mm culture
plates were RA-differentiated, RNA was extracted using an RNeasy kit (Qiagen) with
DNase treatment, rRNA depleted, random-primed cDNA made, and sequencing
subsequently performed using Illumina with HiSeq2000/2500 (>40 million
reads/sample). Sequencing and analysis were done by Idaho State University’s Molecular
Research Core Facility. Alignment of mRNA-Seq was conducted with a standard
protocol as previously described (Trapnell et al., 2012). Briefly, raw reads were initially
trimmed with FASTX-toolkit to remove adapter sequences, and aligned to a reference
genome (human hg19) with TopHat (v2.0.11). To take into account novel splice
isoforms, the de novo transcript assembly from the mapped reads was performed using
cufflinks (v2.2.1) and the assembled transcripts were then merged into a single reference
transcripts using cuffmerge. The resulting full length, mapped transcripts were further
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analyzed using a Bioconductor package, spliceR (Vitting-Seerup, Porse, Sandelin, &
Waage, 2014), and investigated the alternative splicing events of individual genes.
For differential gene expression analysis, the mapped reads were quantified using
cuffdiff and calculate the FPKM (Fragments Per Kilobase of transcript per Million
mapped reads). Genes were discarded from downstream analysis when the calculated
mRNA abundance was lower than FPKM of 0.5, treating them as background noise. The
quantified results were further visualized with CummeRbund (Trapnell et al., 2012) or
custom scripts in R. To investigate whether the expression level of pre-defined sets of
genes correlated to the observed phenotype, the Impact Analysis method was conducted
using iPathwayGuide (Advaita)(Draghici et al., 2003; Khatri, Draghici, Tarca, Hassan, &
Romero, 2007; Tarca et al., 2009). The number of gene-set permutations was set at 1000,
and the most enriched KEGG gene sets (Kanehisa et al., 2014) were selected based on
Normalized Enrichment Scores (NES).
Gaussia Luciferase Protein-Fragment Complementation Assay
Plasmids containing transgenic fusion constructs of syn-hGluc (SynLuc), synhGLuc1 (S1) and syn-hGLuc2 (S2) were transfected (40ng DNA/well) into transgenic
(WT or VPS35 D620N) SH-SY5Y cells in 96 well plates using FuGENE 6 (Promega,
E2691) according to manufacturer’s instructions as previously described (Outeiro et al.,
2008). Media (conditioned media) was transferred to a new 96 well plate 48 hours later
for analysis. The cells were then washed with PBS and new media (without phenol red or
FBS) added. Aggregation of alpha-synuclein was determined by assessing
complementation of luciferase activity. Luciferase activity was measured within the
conditioned media and living cells by automated injection of coelenterazine (40 µM,
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P.J.K., 55779-48-1) into each well and detected using a plate reader (Victor X3
microplate reader, Perkin-Elmer) with a 1 second signal integration time.
Statistical Analysis and Data Management
Statistical analysis was performed using Prism (version 6.0; GraphPad Software,
San Diego, CA). Data between two variables was based on the student’s t-test. Data was
considered significantly different at p < 0.05. The datasets generated during and/or
analyzed during the current study are available from the corresponding author upon
request.
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Supplementary Figures

Figure S1.

WASH1-VPS35 interaction is not detected in SH-SY5Y cells.

Non-transgenic (SH-SY5Y), WT-VPS35, and VPS35-D620N-expressing SHSY5Y cells were RA-differentiated and then WASH1-VPS35 interaction assessed with
co-immunoprecipitation (IP) by pulling transgenic VPS35 down with a V5 antibody. The
blot was then subjected to western blotting with the indicated antibodies (> denotes the
VPS35 band; * signifies a non-specific band found in all samples). Whole cell lysates
(WCL) were also included. Successful VPS35 IP was verified by co-immunoprecipitation
of known interactors VPS29, VPS26, and TBC1D5. As reported by other groups, we do
not observe differential interaction of retromer members (VPS29 and 26A) by VPS35
D620N.
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Figure S2.

VPS35 D620N enhances intracellular alpha-synuclein aggregation.

WT or VPS35 D20N-expressing SH-SY5Y cells were transfected with S1 and S2
plasmids containing full-length alpha-synuclein fused to N-or C-terminal parts of human
Gaussia luciferase. Upon aggregation of alpha-synuclein, complementary portions of
luciferase produced a functional enzyme that was detected by adding luciferase substrate
coelenterazine. Full length luciferase as well as alpha-synuclein conjugated to full-length
luciferase were also examined as basal expression controls. VPS35 D620N-expressing
cells exhibited significantly elevated alpha-synuclein aggregation compared to WT cells
(student’s t-test; **P>0.05; Error bars = SEM).
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Figure S3.

RNA-Seq data assessment.

Alignment statistics for sequencing reads (A). mRNA abundance distribution
(density plot) for all genes quantified from RNA-seq analysis (B). Each replicate was
plotted individually and overlaid to show there is no distribution bias. FPKM ≥ 0.5 was
arbitrary set as cut-off value for downstream analysis. A scatter plot comparing wild-type
(wt) and VPS35-D620N (mut) samples (C). Each dot represents the average expression
level (FPKM) of individual genes calculated from three biological replicates. The vast
majority of genes were expressed similarly in wt (VPS35) and mut (VPS35-D620N)
cells, but genes that were differentially expressed are remotely located from the diagonal
dashed-line. A dendrogram of all quantified mRNA from RNA-seq analysis (D).
Clustering among biological replicates suggested that the D620N mutation causes
differential gene expression.

45

REFERENCES
Ando, M., Funayama, M., Li, Y., Kashihara, K., Murakami, Y., Ishizu, N., … Hattori, N.
(2012). VPS35 mutation in Japanese patients with typical Parkinson’s disease.
Movement Disorders, 27(11), 1413–1417. http://doi.org/10.1002/mds.25145
Appel, J. R., Ye, S., Tang, F., Sun, D., Zhang, H., Mei, L., & Xiong, W.-C. (2018).
Increased Microglial Activity, Impaired Adult Hippocampal Neurogenesis, and
Depressive-like Behavior in Microglial VPS35-Depleted Mice. The Journal of
Neuroscience, 38(26), 5949–5968. http://doi.org/10.1523/JNEUROSCI.362117.2018
Arighi, C. N., Hartnell, L. M., Aguilar, R. C., Haft, C. R., & Bonifacino, J. S. (2004).
Role of the mammalian retromer in sorting of the cation-independent mannose 6phosphate receptor. The Journal of Cell Biology, 165(1), 123–133.
http://doi.org/10.1083/jcb.200312055
Ascherio, A., & Schwarzschild, M. A. (2016). The epidemiology of Parkinson’s disease:
risk factors and prevention. The Lancet Neurology, 15(12), 1257–1272.
http://doi.org/10.1016/S1474-4422(16)30230-7
Ashrafi, G., & Schwarz, T. L. (2013). The pathways of mitophagy for quality control and
clearance of mitochondria. Cell Death & Differentiation, 20(1), 31–42.
http://doi.org/10.1038/cdd.2012.81
Assmann, V., Jenkinson, D., Marshall, J. F., & Hart, I. R. (1999). The intracellular
hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin
filaments. Journal of Cell Science, 112 ( Pt 2, 3943–3954.
Aufschnaiter, A., Kohler, V., & Büttner, S. (2017). Taking out the garbage: cathepsin D
and calcineurin in neurodegeneration. Neural Regeneration Research, 12(11),
1776. http://doi.org/10.4103/1673-5374.219031

46
Bahouth, S. W., & Nooh, M. M. (2017). Barcoding of GPCR trafficking and signaling
through the various trafficking roadmaps by compartmentalized signaling
networks. Cellular Signalling, 36, 42–55.
http://doi.org/10.1016/j.cellsig.2017.04.015
Barth, S., Glick, D., & Macleod, K. F. (2010). Autophagy: Assays and artifacts. Journal
of Pathology, 221(2), 117–124. http://doi.org/10.1002/path.2694
Beard, J. D., Steege, A. L., Ju, J., Lu, J., Luckhaupt, S. E., & Schubauer-Berigan, M. K.
(2017). Mortality from Amyotrophic Lateral Sclerosis and Parkinson’s Disease
Among Different Occupation Groups - United States, 1985-2011. MMWR.
Morbidity and Mortality Weekly Report, 66(27), 718–722.
http://doi.org/10.15585/mmwr.mm6627a2
Belenkaya, T. Y., Wu, Y., Tang, X., Zhou, B., Cheng, L., Sharma, Y. V., … Lin, X.
(2008). The Retromer Complex Influences Wnt Secretion by Recycling Wntless
from Endosomes to the Trans-Golgi Network. Developmental Cell, 14(1), 120–
131. http://doi.org/10.1016/j.devcel.2007.12.003
Blanckenberg, J., Ntsapi, C., Carr, J. A., & Bardien, S. (2014). EIF4G1 R1205H and
VPS35 D620N mutations are rare in Parkinson’s disease from South Africa.
Neurobiology of Aging, 35(2), 445.e1-3.
http://doi.org/10.1016/j.neurobiolaging.2013.08.023
Bonifacino, J. S., & Hurley, J. H. (2008). Retromer. Current Opinion in Cell Biology,
20(4), 427–436. http://doi.org/10.1016/j.ceb.2008.03.009
Bowman, S. L., Shiwarski, D. J., & Puthenveedu, M. A. (2016). Distinct G proteincoupled receptor recycling pathways allow spatial control of downstream G
protein signaling. The Journal of Cell Biology, 214(7), 797–806.
http://doi.org/10.1083/jcb.201512068
Braschi, E., Goyon, V., Zunino, R., Mohanty, A., Xu, L., & McBride, H. M. (2010).
Vps35 mediates vesicle transport between the mitochondria and peroxisomes.
Current Biology : CB, 20(14), 1310–5. http://doi.org/10.1016/j.cub.2010.05.066

47
Brundin, P., & Melki, R. (2017). Prying into the Prion Hypothesis for Parkinson’s
Disease. The Journal of Neuroscience, 37(41), 9808–9818.
http://doi.org/10.1523/JNEUROSCI.1788-16.2017
Bunnett, N. W., & Cottrell, G. S. (2010). Trafficking and signaling of G protein-coupled
receptors in the nervous system: implications for disease and therapy. CNS &
Neurological Disorders Drug Targets, 9(5), 539–56.
Calatayud, C., Carola, G., Consiglio, A., & Raya, A. (2017). Modeling the genetic
complexity of Parkinson’s disease by targeted genome edition in iPS cells.
Current Opinion in Genetics & Development, 46, 123–131.
http://doi.org/10.1016/j.gde.2017.06.002
Cataldi, S., Follett, J., Fox, J. D., Tatarnikov, I., Kadgien, C., Gustavsson, E. K., …
Farrer, M. J. (2018). Altered dopamine release and monoamine transporters in
Vps35 p.D620N knock-in mice. Npj Parkinson’s Disease, 4(1), 27.
http://doi.org/10.1038/s41531-018-0063-3
Chan, A. S. M., Clairfeuille, T., Landao-Bassonga, E., Kinna, G., Ng, P. Y., Loo, L. S.,
… Pavlos, N. J. (2016). Sorting nexin 27 couples PTHR trafficking to retromer
for signal regulation in osteoblasts during bone growth. Molecular Biology of the
Cell, 27(8), 1367–82. http://doi.org/10.1091/mbc.E15-12-0851
Chen, Y., Chen, K., Song, W., Chen, X., Cao, B., Huang, R., … Shang, H.-F. (2013).
VPS35 Asp620Asn and EIF4G1 Arg1205His mutations are rare in Parkinson
disease from Southwest China. Neurobiology of Aging, 34(6), 1709.e7-1709.e8.
http://doi.org/10.1016/j.neurobiolaging.2012.11.003
Choi, A. M. K., Ryter, S. W., & Levine, B. (2013). Autophagy in human health and
disease. The New England Journal of Medicine, 368(19), 1845–1846.
http://doi.org/10.1056/NEJMc1303158
Choi, K. H., Basma, H., Singh, J., & Cheng, P.-W. (2005). Activation of CMV promotercontrolled glycosyltransferase and beta -galactosidase glycogenes by butyrate,
tricostatin A, and 5-aza-2’-deoxycytidine. Glycoconjugate Journal, 22(1–2), 63–
69. http://doi.org/10.1007/s10719-005-0326-1

48
Choy, R. W.-Y., Park, M., Temkin, P., Herring, B. E., Marley, A., Nicoll, R. A., &
von Zastrow, M. (2014). Retromer Mediates a Discrete Route of Local Membrane
Delivery to Dendrites. Neuron, 82(1), 55–62.
http://doi.org/10.1016/j.neuron.2014.02.018
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M.
(2010). Pathogenic lysosomal depletion in Parkinson’s disease. The Journal of
Neuroscience: The Official Journal of the Society for Neuroscience, 30(37),
12535–12544. http://doi.org/10.1523/JNEUROSCI.1920-10.2010
Dehay, B., Martinez-Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson,
M. R., … Bezard, E. (2013). Lysosomal impairment in Parkinson’s disease.
Movement Disorders: Official Journal of the Movement Disorder Society, 28(6),
725–732. http://doi.org/10.1002/mds.25462
Deng, H., Gao, K., & Jankovic, J. (2013). The VPS35 gene and Parkinson’s disease.
Movement Disorders, 28(5), 569–575. http://doi.org/10.1002/mds.25430
Deng, H., Xu, H., Deng, X., Song, Z., Zheng, W., Gao, K., … Tang, J. (2012). VPS35
mutation in Chinese Han patients with late-onset Parkinson’s disease. European
Journal of Neurology, 19(9), e96-7. http://doi.org/10.1111/j.14681331.2012.03800.x
Dengjel, J., Høyer-Hansen, M., Nielsen, M. O., Eisenberg, T., Harder, L. M., Schandorff,
S., … Andersen, J. S. (2012). Identification of autophagosome-associated proteins
and regulators by quantitative proteomic analysis and genetic screens. Molecular
& Cellular Proteomics: MCP, 11(3), M111.014035.
http://doi.org/10.1074/mcp.M111.014035
Dhungel, N., Eleuteri, S., Li, L., Kramer, N. J., Chartron, J. W., Spencer, B., … Gitler, A.
D. (2015). Parkinson’s Disease Genes VPS35 and EIF4G1 Interact Genetically
and Converge on α-Synuclein. Neuron, 85(1), 76–87.
http://doi.org/10.1016/j.neuron.2014.11.027

49
Draghici, S., Khatri, P., Bhavsar, P., Shah, A., Krawetz, S. A., & Tainsky, M. A. (2003).
Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare,
Onto-Design and Onto-Translate. Nucleic Acids Research, 31(13), 3775–3781.
Elbaz, A., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog,
J. E., … Rocca, W. A. (2002). Risk tables for parkinsonism and Parkinson’s
disease. Journal of Clinical Epidemiology, 55(1), 25–31.
http://doi.org/10.1016/S0895-4356(01)00425-5
Feinstein, T. N., Wehbi, V. L., Ardura, J. A., Wheeler, D. S., Ferrandon, S., Gardella, T.
J., & Vilardaga, J.-P. (2011). Retromer terminates the generation of cAMP by
internalized PTH receptors. Nature Chemical Biology, 7(5), 278–284.
http://doi.org/10.1038/nchembio.545
Follett, J., Bugarcic, A., Collins, B. M., & Teasdale, R. D. (2017). Retromer’s Role in
Endosomal Trafficking and Impaired Function in Neurodegenerative Diseases.
Current Protein & Peptide Science, 18(7), 687–701.
http://doi.org/10.2174/1389203717666160311121246
Follett, J., Norwood, S. J., Hamilton, N. A., Mohan, M., Kovtun, O., Tay, S., …
Teasdale, R. D. (2014a). The Vps35 D620N Mutation Linked to Parkinson’s
Disease Disrupts the Cargo Sorting Function of Retromer. Traffic, 15(2), 230–
244. http://doi.org/10.1111/tra.12136
Follett, J., Norwood, S. J., Hamilton, N. a, Mohan, M., Kovtun, O., Tay, S., … Teasdale,
R. D. (2014b). The Vps35 D620N mutation linked to Parkinson’s disease disrupts
the cargo sorting function of retromer. Traffic (Copenhagen, Denmark), 15(2),
230–44. http://doi.org/10.1111/tra.12136
Fuse, A., Furuya, N., Kakuta, S., Inose, A., Sato, M., Koike, M., … Hattori, N. (2015).
VPS29-VPS35 intermediate of retromer is stable and may be involved in the
retromer complex assembly process. FEBS Letters, 589(13), 1430–1436.
http://doi.org/10.1016/j.febslet.2015.04.040
Gagliardi, M., Annesi, G., Tarantino, P., Nicoletti, G., & Quattrone, A. (2014).
Frequency of the ASP620ASN mutation in VPS35 and Arg1205His mutation in

50
EIF4G1 in familial Parkinson’s disease from South Italy. Neurobiology of Aging,
35(10), 2422.e1-2422.e2. http://doi.org/10.1016/j.neurobiolaging.2014.04.020
Gallon, M., & Cullen, P. J. (2015). Retromer and sorting nexins in endosomal sorting.
Biochemical Society Transactions, 43(1), 33–47.
http://doi.org/10.1042/BST20140290
Gambardella, S., Biagioni, F., Ferese, R., Busceti, C. L., Frati, A., Novelli, G., … Fornai,
F. (2016). Vacuolar Protein Sorting Genes in Parkinson’s Disease: A Re-appraisal
of Mutations Detection Rate and Neurobiology of Disease. Frontiers in
Neuroscience, 10, 532. http://doi.org/10.3389/fnins.2016.00532
Gomez, T. S., & Billadeau, D. D. (2009). A FAM21-containing WASH complex
regulates retromer-dependent sorting. Developmental Cell, 17(5), 699–711.
http://doi.org/10.1016/j.devcel.2009.09.009
Goswami, P., Joshi, N., & Singh, S. (2017). Neurodegenerative signaling factors and
mechanisms in Parkinson’s pathology. Toxicology in Vitro, 43(December 2016),
104–112. http://doi.org/10.1016/j.tiv.2017.06.008
Guella, I., Soldà, G., Cilia, R., Pezzoli, G., Asselta, R., Duga, S., & Goldwurm, S. (2012).
The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson’s
disease. Movement Disorders, 27(6), 800–801. http://doi.org/10.1002/mds.24927
Guo, J., Sun, Q., Lv, Z., Yu, R., Li, K., Zhang, Y., … Tang, B. (2012). VPS35 gene
variants are not associated with Parkinson’s disease in the mainland Chinese
population. Parkinsonism & Related Disorders, 18(8), 983–985.
http://doi.org/10.1016/j.parkreldis.2012.05.002
Gustavsson, E. K., Guella, I., Trinh, J., Szu-Tu, C., Rajput, A., Rajput, A. H., … Farrer,
M. J. (2015). Genetic variability of the retromer cargo recognition complex in
parkinsonism. Movement Disorders, 30(4), 580–584.
http://doi.org/10.1002/mds.26104
Haelterman, N. A., Yoon, W. H., Sandoval, H., Jaiswal, M., Shulman, J. M., & Bellen, H.
J. (2014). A Mitocentric View of Parkinson’s Disease. Annual Review of

51
Neuroscience, 37(1), 137–159. http://doi.org/10.1146/annurev-neuro-071013014317
Hao, Y.-H., Doyle, J. M., Ramanathan, S., Gomez, T. S., Jia, D., Xu, M., … Potts, P. R.
(2013). Regulation of WASH-dependent actin polymerization and protein
trafficking by ubiquitination. Cell, 152(5), 1051–1064.
http://doi.org/10.1016/j.cell.2013.01.051
Hauser, D. N., & Hastings, T. G. (2013). Mitochondrial dysfunction and oxidative stress
in Parkinson’s disease and monogenic parkinsonism. Neurobiology of Disease,
51, 35–42. http://doi.org/10.1016/j.nbd.2012.10.011
He, C., & Klionsky, D. J. (2009). Regulation mechanisms and signaling pathways of
autophagy. Annual Review of Genetics, 43, 67–93.
http://doi.org/10.1146/annurev-genet-102808-114910
Helley, M. P., Pinnell, J., Sportelli, C., & Tieu, K. (2017). Mitochondria: A Common
Target for Genetic Mutations and Environmental Toxicants in Parkinson’s
Disease. Frontiers in Genetics, 8, 177. http://doi.org/10.3389/fgene.2017.00177
Inoshita, T., Arano, T., Hosaka, Y., Meng, H., Umezaki, Y., Kosugi, S., … Hattori, N.
(2017). Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis
through the endosomal pathway in Drosophila. Human Molecular Genetics,
26(15), 2933–2948. http://doi.org/10.1093/hmg/ddx179
Ishizu, N., Yui, D., Hebisawa, A., Aizawa, H., Cui, W., Fujita, Y., … Watase, K. (2016).
Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice.
Human Molecular Genetics, 25(20), ddw279. http://doi.org/10.1093/hmg/ddw279
Jankovic, J., & Stacy, M. (2007). Medical management of levodopa-associated motor
complications in patients with Parkinson’s disease. CNS Drugs, 21(8), 677–692.
Janku, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011). Autophagy as a target
for anticancer therapy. Nature Reviews. Clinical Oncology, 8(9), 528–539.
http://doi.org/10.1038/nrclinonc.2011.71
Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., & Tanabe, M. (2014).
Data, information, knowledge and principle: back to metabolism in KEGG.

52
Nucleic Acids Research, 42(Database issue), D199-205.
http://doi.org/10.1093/nar/gkt1076
Khatri, P., Draghici, S., Tarca, A. L., Hassan, S. S., & Romero, R. (2007). A System
Biology Approach for the Steady-State Analysis of Gene Signaling Networks. In
Progress in Pattern Recognition, Image Analysis and Applications (pp. 32–41).
Springer, Berlin, Heidelberg. http://doi.org/10.1007/978-3-540-76725-1_4
Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A.,
Adeli, K., … Zuckerbraun, B. (2012). Guidelines for the use and interpretation of
assays for monitoring autophagy. Autophagy, 8(4), 445–544.
http://doi.org/10.4161/auto.19496
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008). Lewy
body–like pathology in long-term embryonic nigral transplants in Parkinson’s
disease. Nature Medicine, 14(5), 504–506. http://doi.org/10.1038/nm1747
Korecka, J. A., van Kesteren, R. E., Blaas, E., Spitzer, S. O., Kamstra, J. H., Smit, A. B.,
Bossers, K. (2013). Phenotypic characterization of retinoic acid differentiated SHSY5Y cells by transcriptional profiling. PloS One, 8(5), e63862.
http://doi.org/10.1371/journal.pone.0063862
Korolchuk, V. I., Schutz, M. M., Gomez-Llorente, C., Rocha, J., Lansu, N. R., Collins, S.
M., … O’Kane, C. J. (2007). Drosophila Vps35 function is necessary for normal
endocytic trafficking and actin cytoskeleton organisation. Journal of Cell Science,
120(24), 4367–4376. http://doi.org/10.1242/jcs.012336
Koschmidder, E., Mollenhauer, B., Kasten, M., Klein, C., & Lohmann, K. (2014).
Mutations in VPS26A are not a frequent cause of Parkinson’s disease.
Neurobiology of Aging, 35(6), 1512.e1-2.
http://doi.org/10.1016/j.neurobiolaging.2013.12.016
Krishna, A., Biryukov, M., Trefois, C., Antony, P. M. A., Hussong, R., Lin, J., … May,
P. (2014). Systems genomics evaluation of the SH-SY5Y neuroblastoma cell line
as a model for Parkinson’s disease. BMC Genomics, 15(1), 1154.
http://doi.org/10.1186/1471-2164-15-1154

53
Kumar, K. R., Weissbach, A., Heldmann, M., Kasten, M., Tunc, S., Sue, C. M., …
Lohmann, K. (2012). Frequency of the D620N mutation in VPS35 in Parkinson
disease. Archives of Neurology, 69(10), 1360–4.
http://doi.org/10.1001/archneurol.2011.3367
La Spada, A. R., & Taylor, J. P. (2010). Repeat expansion disease: progress and puzzles
in disease pathogenesis. Nature Reviews. Genetics, 11(4), 247–258.
http://doi.org/10.1038/nrg2748
Lau, L. M. L. De, & Breteler, M. M. B. (2006). Epidemiology of Parkinson ’ s disease.
Lancet Neurol, 5(June), 525–535. http://doi.org/18(3) : 231 – 238
Lesage, S., Condroyer, C., Klebe, S., Honore, A., Tison, F., Brefel-Courbon, C., … Brice,
A. (2012). Identification of VPS35 mutations replicated in French families with
Parkinson disease. Neurology, 78(18), 1449–1450.
http://doi.org/10.1212/WNL.0b013e318253d5f2
Levine, B., & Kroemer, G. (2008). Autophagy in the Pathogenesis of Disease. Cell,
132(1), 27–42. http://doi.org/10.1016/j.cell.2007.12.018
Li, C., Shah, S. Z. A., Zhao, D., & Yang, L. (2016). Role of the Retromer Complex in
Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 8, 42.
http://doi.org/10.3389/fnagi.2016.00042
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., … Brundin, P.
(2008). Lewy bodies in grafted neurons in subjects with Parkinson’s disease
suggest host-to-graft disease propagation. Nature Medicine, 14(5), 501–503.
http://doi.org/10.1038/nm1746
Lin, S.-L., Chang, D., & Ying, S.-Y. (2007). Hyaluronan stimulates transformation of
androgen-independent prostate cancer. Carcinogenesis, 28(2), 310–320.
http://doi.org/10.1093/carcin/bgl134
Linhart, R., Wong, S., Cao, J., Tran, M., Huynh, A., Ardrey, C., … Venderova, K.
(2014). Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and
shortened lifespan in Drosophila expressing a Parkinson’s disease mutant of

54
Leucine-rich repeat kinase 2 (LRRK2). Molecular Neurodegeneration, 9(1), 23.
http://doi.org/10.1186/1750-1326-9-23
Loring, J. F. (2018). Autologous Induced Pluripotent Stem Cell-Derived Neurons to Treat
Parkinson’s Disease. Stem Cells and Development, 27(14), 958–959.
http://doi.org/10.1089/scd.2018.0107
Lucas, M., Gershlick, D. C., Vidaurrazaga, A., Rojas, A. L., Bonifacino, J. S., & Hierro,
A. (2016). Structural Mechanism for Cargo Recognition by the Retromer
Complex. Cell, 167(6), 1623–1635.e14. http://doi.org/10.1016/j.cell.2016.10.056
Lucin, K. M., O’Brien, C. E., Bieri, G., Czirr, E., Mosher, K. I., Abbey, R. J., … WyssCoray, T. (2013). Microglial Beclin 1 Regulates Retromer Trafficking and
Phagocytosis and Is Impaired in Alzheimer’s Disease. Neuron, 79(5), 873–886.
http://doi.org/10.1016/j.neuron.2013.06.046
Luo, W., Friedman, M. S., Shedden, K., Hankenson, K. D., & Woolf, P. J. (2009).
GAGE: generally applicable gene set enrichment for pathway analysis. BMC
Bioinformatics, 10, 161. http://doi.org/10.1186/1471-2105-10-161
Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M., & Klionsky, D. J. (2012). The role of
autophagy in Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine,
2(4). http://doi.org/10.1101/cshperspect.a009357
MacLeod, D. A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B. D., …
Abeliovich, A. (2013). RAB7L1 interacts with LRRK2 to modify intraneuronal
protein sorting and Parkinson’s disease risk. Neuron, 77(3), 425–39.
http://doi.org/10.1016/j.neuron.2012.11.033
Maharjan, A. S., Pilling, D., & Gomer, R. H. (2011). High and low molecular weight
hyaluronic acid differentially regulate human fibrocyte differentiation. PloS One,
6(10), e26078. http://doi.org/10.1371/journal.pone.0026078
Malgaroli, A., Vallar, L., & Zimarino, V. (2006). Protein homeostasis in neurons and its
pathological alterations. Current Opinion in Neurobiology, 16(3), 270–274.
http://doi.org/10.1016/j.conb.2006.05.009

55
Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., … Tanner, C.
(2018). Prevalence of Parkinson’s disease across North America. Npj Parkinson’s
Disease, 4(1), 21. http://doi.org/10.1038/s41531-018-0058-0
Maxwell, C. A., Keats, J. J., Crainie, M., Sun, X., Yen, T., Shibuya, E., … Pilarski, L. M.
(2003). RHAMM is a centrosomal protein that interacts with dynein and
maintains spindle pole stability. Molecular Biology of the Cell, 14(6), 2262–2276.
http://doi.org/10.1091/mbc.E02-07-0377
Maxwell, C. A., McCarthy, J., & Turley, E. (2008). Cell-surface and mitotic-spindle
RHAMM: moonlighting or dual oncogenic functions? Journal of Cell Science,
121(Pt 7), 925–932. http://doi.org/10.1242/jcs.022038
Maxwell, C. A., Rasmussen, E., Zhan, F., Keats, J. J., Adamia, S., Strachan, E., …
Reiman, T. (2004). RHAMM expression and isoform balance predict aggressive
disease and poor survival in multiple myeloma. Blood, 104(4), 1151–1158.
http://doi.org/10.1182/blood-2003-11-4079
McGarvey, J. C., Xiao, K., Bowman, S. L., Mamonova, T., Zhang, Q., Bisello, A., …
Friedman, P. A. (2016). Actin-Sorting Nexin 27 (SNX27)-Retromer Complex
Mediates Rapid Parathyroid Hormone Receptor Recycling. Journal of Biological
Chemistry, 291(21), 10986–11002. http://doi.org/10.1074/jbc.M115.697045
McGough, I. J., & Cullen, P. J. (2011). Recent advances in retromer biology. Traffic
(Copenhagen, Denmark), 12(8), 963–71. http://doi.org/10.1111/j.16000854.2011.01201.x
McGough, I. J., Steinberg, F., Jia, D., Barbuti, P. A., Mcmillan, K. J., Heesom, K. J., …
Cullen, P. J. (2014). Report Retromer Binding to FAM21 and the WASH
Complex Is Perturbed by the Parkinson Disease-Linked VPS35 ( D620N )
Mutation. Current Biology, 24(14), 1670–1676.
http://doi.org/10.1016/j.cub.2014.06.024
McGough, I. J., Steinberg, F., Jia, D., Barbuti, P. A., McMillan, K. J., Heesom, K. J., …
Cullen, P. J. (2014). Retromer binding to FAM21 and the WASH complex is

56
perturbed by the Parkinson disease-linked VPS35(D620N) mutation. Current
Biology: CB, 24(14), 1670–1676. http://doi.org/10.1016/j.cub.2014.06.024
Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N. K., Martinez, T. N., … Alessi, D.
R. (2018). The Parkinson’s disease VPS35[D620N] mutation enhances LRRK2mediated Rab protein phosphorylation in mouse and human. Biochemical
Journal, 475(11), 1861–1883. http://doi.org/10.1042/BCJ20180248
Miura, E., Hasegawa, T., Konno, M., Suzuki, M., Sugeno, N., Fujikake, N., … Aoki, M.
(2014). VPS35 dysfunction impairs lysosomal degradation of α-synuclein and
exacerbates neurotoxicity in a Drosophila model of Parkinson’s disease.
Neurobiology of Disease, 71, 1–13. http://doi.org/10.1016/j.nbd.2014.07.014
Mohapatra, S., Yang, X., Wright, J. A., Turley, E. A., & Greenberg, A. H. (1996).
Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2
and cyclin B1 expression. The Journal of Experimental Medicine, 183(4), 1663–
1668.
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J.,
… Groop, L. C. (2003). PGC-1alpha-responsive genes involved in oxidative
phosphorylation are coordinately downregulated in human diabetes. Nature
Genetics, 34(3), 267–273. http://doi.org/10.1038/ng1180
Mullin, S., & Schapira, A. (2013). α-Synuclein and Mitochondrial Dysfunction in
Parkinson’s Disease. Molecular Neurobiology, 47(2), 587–597.
http://doi.org/10.1007/s12035-013-8394-x
Munsie, L. N., Milnerwood, A. J., Seibler, P., Beccano-Kelly, D. A., Tatarnikov, I.,
Khinda, J., … Farrer, M. J. (2015). Retromer-dependent neurotransmitter receptor
trafficking to synapses is altered by the Parkinson’s disease VPS35 mutation
p.D620N. Human Molecular Genetics, 24(6), 1691–1703.
http://doi.org/10.1093/hmg/ddu582
Nayerossadat, N., Maedeh, T., & Ali, P. A. (2012). Viral and nonviral delivery systems
for gene delivery. Advanced Biomedical Research, 1, 27.
http://doi.org/10.4103/2277-9175.98152

57
Neame, S. J., Uff, C. R., Sheikh, H., Wheatley, S. C., & Isacke, C. M. (1995). CD44
exhibits a cell type dependent interaction with triton X-100 insoluble, lipid rich,
plasma membrane domains. Journal of Cell Science, 108 ( Pt 9, 3127–3135.
Onodera, Y., Teramura, T., Takehara, T., & Fukuda, K. (2015). Hyaluronic acid regulates
a key redox control factor Nrf2 via phosphorylation of Akt in bovine articular
chondrocytes. FEBS Open Bio, 5, 476–484.
http://doi.org/10.1016/j.fob.2015.05.007
Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., …
McLean, P. J. (2008). Formation of toxic oligomeric alpha-synuclein species in
living cells. PloS One, 3(4), e1867. http://doi.org/10.1371/journal.pone.0001867
Patel, D., & Witt, S. N. (2018). Sorting Out the Role of α-Synuclein in RetromerMediated Endosomal Protein Sorting. Journal of Experimental Neuroscience, 12,
117906951879621. http://doi.org/10.1177/1179069518796215
Pavlos, N. J., & Friedman, P. A. (2017). GPCR Signaling and Trafficking: The Long and
Short of It. Trends in Endocrinology & Metabolism, 28(3), 213–226.
http://doi.org/10.1016/j.tem.2016.10.007
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014). The prevalence of
Parkinson’s disease: A systematic review and meta-analysis. Movement
Disorders, 29(13), 1583–1590. http://doi.org/10.1002/mds.25945
Reitz, C. (2018). Retromer Dysfunction and Neurodegenerative Disease. Current
Genomics, 19(4), 279–288. http://doi.org/10.2174/1389202919666171024122809
Riedel, M., Goldbaum, O., Schwarz, L., Schmitt, S., & Richter-Landsberg, C. (2010). 17AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of
autophagy. PloS One, 5(1), e8753. http://doi.org/10.1371/journal.pone.0008753
Savani, R. C., Cao, G., Pooler, P. M., Zaman, A., Zhou, Z., & DeLisser, H. M. (2001).
Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for
HA-mediated motility in endothelial cell function and angiogenesis. The Journal
of Biological Chemistry, 276(39), 36770–36778.
http://doi.org/10.1074/jbc.M102273200

58
Schütze, A., Vogeley, C., Gorges, T., Twarock, S., Butschan, J., Babayan, A., … Röck,
K. (2016). RHAMM splice variants confer radiosensitivity in human breast cancer
cell lines. Oncotarget, 7(16), 21428–21440.
http://doi.org/10.18632/oncotarget.7258
Scott, K. L., Kabbarah, O., Liang, M.-C., Ivanova, E., Anagnostou, V., Wu, J., … Chin,
L. (2009). GOLPH3 modulates mTOR signalling and rapamycin sensitivity in
cancer. Nature, 459(7250), 1085–1090. http://doi.org/10.1038/nature08109
Seaman, M. N. J. (2012). The retromer complex - endosomal protein recycling and
beyond. Journal of Cell Science, 125(Pt 20), 4693–702.
http://doi.org/10.1242/jcs.103440
Seaman, M. N. J., Harbour, M. E., Tattersall, D., Read, E., & Bright, N. (2009).
Membrane recruitment of the cargo-selective retromer subcomplex is catalysed by
the small GTPase Rab7 and inhibited by the Rab-GAP TBC1D5. Journal of Cell
Science, 122(14), 2371–2382. http://doi.org/10.1242/jcs.048686
Seaman, M. N., McCaffery, J. M., & Emr, S. D. (1998). A membrane coat complex
essential for endosome-to-Golgi retrograde transport in yeast. The Journal of Cell
Biology, 142(3), 665–81.
Shannon, B., Soto-Ortolaza, A., Rayaprolu, S., Cannon, H. D., Labbé, C., Benitez, B. A.,
… Ross, O. A. (2014). Genetic variation of the retromer subunits VPS26A/BVPS29 in Parkinson’s disease. Neurobiology of Aging, 35(8), 1958.e1-1958.e2.
http://doi.org/10.1016/j.neurobiolaging.2014.03.004
Sharma, M., Ioannidis, J. P. A., Aasly, J. O., Annesi, G., Brice, A., Bertram, L., …
Krüger, R. (2012). A multi-centre clinico-genetic analysis of the VPS35 gene in
Parkinson disease indicates reduced penetrance for disease-associated variants.
Journal of Medical Genetics, 49(11), 721–726. http://doi.org/10.1136/jmedgenet2012-101155
Sheerin, U.-M., Charlesworth, G., Bras, J., Guerreiro, R., Bhatia, K., Foltynie, T., …
Wood, N. (2012). Screening for VPS35 mutations in Parkinson’s disease.

59
Neurobiology of Aging, 33(4), 838.e1-5.
http://doi.org/10.1016/j.neurobiolaging.2011.10.032
Shipley, M. M., Mangold, C. A., & Szpara, M. L. (2016). Differentiation of the SHSY5Y Human Neuroblastoma Cell Line. Journal of Visualized Experiments,
(108), 1–11. http://doi.org/10.3791/53193
Small, S. A., Kent, K., Pierce, A., Leung, C., Kang, M. S., Okada, H., … Kim, T.-W.
(2005). Model-guided microarray implicates the retromer complex in Alzheimer’s
disease. Annals of Neurology, 58(6), 909–19. http://doi.org/10.1002/ana.20667
Small, S. A., & Petsko, G. A. (2015). Retromer in Alzheimer disease, Parkinson disease
and other neurological disorders. Nature Reviews Neuroscience, 16(3), 126–132.
http://doi.org/10.1038/nrn3896
Sohr, S., & Engeland, K. (2008). RHAMM is differentially expressed in the cell cycle
and downregulated by the tumor suppressor p53. Cell Cycle (Georgetown, Tex.),
7(21), 3448–3460. http://doi.org/10.4161/cc.7.21.7014
Sposini, S., Jean-Alphonse, F. G., Ayoub, M. A., Oqua, A., West, C., Lavery, S., …
Hanyaloglu, A. C. (2017). Integration of GPCR Signaling and Sorting from Very
Early Endosomes via Opposing APPL1 Mechanisms. Cell Reports, 21(10), 2855–
2867. http://doi.org/10.1016/j.celrep.2017.11.023
Subramaniam, S. R., & Chesselet, M.-F. (2013). Mitochondrial dysfunction and oxidative
stress in Parkinson’s disease. Progress in Neurobiology, 106–107, 17–32.
http://doi.org/10.1016/j.pneurobio.2013.04.004
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M.
A., … Mesirov, J. P. (2005). Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proceedings of the
National Academy of Sciences of the United States of America, 102(43), 15545–
15550. http://doi.org/10.1073/pnas.0506580102
Sudhaman, S., Behari, M., Govindappa, S. T., Muthane, U. B., Juyal, R. C., & Thelma,
B. K. (2013). VPS35 and EIF4G1 mutations are rare in Parkinson’s disease

60
among Indians. Neurobiology of Aging, 34(10), 2442.e1-2442.e3.
http://doi.org/10.1016/j.neurobiolaging.2013.04.025
Sugiura, A., McLelland, G.-L., Fon, E. A., & McBride, H. M. (2014). A new pathway for
mitochondrial quality control: mitochondrial-derived vesicles. The EMBO
Journal, 33(19), 2142–2156. http://doi.org/10.15252/embj.201488104
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017). Parkinson’s Disease Is Not
Simply a Prion Disorder. The Journal of Neuroscience, 37(41), 9799–9807.
http://doi.org/10.1523/JNEUROSCI.1787-16.2017
Tabuchi, M., Yanatori, I., Kawai, Y., & Kishi, F. (2010). Retromer-mediated direct
sorting is required for proper endosomal recycling of the mammalian iron
transporter DMT1. Journal of Cell Science, 123(5), 756–766.
http://doi.org/10.1242/jcs.060574
Tang, F.-L., Erion, J. R., Tian, Y., Liu, W., Yin, D.-M., Ye, J., … Xiong, W.-C. (2015).
VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of
Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for Synuclein Degradation and Prevention of Pathogenesis of Parkinson’s Disease.
Journal of Neuroscience, 35(29), 10613–10628.
http://doi.org/10.1523/JNEUROSCI.0042-15.2015
Tang, F.-L., Liu, W., Hu, J.-X., Erion, J. R., Ye, J., Mei, L., & Xiong, W.-C. (2015).
VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by
Impairing Mitochondrial Fusion and Function. Cell Reports, 12(10), 1631–1643.
http://doi.org/10.1016/j.celrep.2015.08.001
Tanik, S. A., Schultheiss, C. E., Volpicelli-Daley, L. A., Brunden, K. R., & Lee, V. M. Y.
(2013). Lewy body-like α-synuclein aggregates resist degradation and impair
macroautophagy. The Journal of Biological Chemistry, 288(21), 15194–15210.
http://doi.org/10.1074/jbc.M113.457408
Tarca, A. L., Draghici, S., Khatri, P., Hassan, S. S., Mittal, P., Kim, J.-S., … Romero, R.
(2009). A novel signaling pathway impact analysis. Bioinformatics (Oxford,
England), 25(1), 75–82. http://doi.org/10.1093/bioinformatics/btn577

61
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002). Toxic proteins in neurodegenerative
disease. Science (New York, N.Y.), 296(5575), 1991–1995.
http://doi.org/10.1126/science.1067122
Taylor, K. S. M., Cook, J. A., & Counsell, C. E. (2007). Heterogeneity in male to female
risk for Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry,
78(8), 905–6. http://doi.org/10.1136/jnnp.2006.104695
Tian, Y., Tang, F.-L., Sun, X., Wen, L., Mei, L., Tang, B.-S., & Xiong, W.-C. (2015).
VPS35-deficiency results in an impaired AMPA receptor trafficking and
decreased dendritic spine maturation. Molecular Brain, 8(1), 70.
http://doi.org/10.1186/s13041-015-0156-4
Tofaris, G. K. (2012). Lysosome-dependent pathways as a unifying theme in Parkinson’s
disease. Movement Disorders, 27(11), 1364–1369.
http://doi.org/10.1002/mds.25136
Trapasso, S., & Allegra, E. (2012). Role of CD44 as a marker of cancer stem cells in
head and neck cancer. Biologics: Targets & Therapy, 6, 379–383.
http://doi.org/10.2147/BTT.S37906
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., … Pachter, L.
(2012). Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and Cufflinks. Nature Protocols, 7(3), 562–578.
http://doi.org/10.1038/nprot.2012.016
Trousdale, C., & Kim, K. (2015). Retromer: Structure, function, and roles in mammalian
disease. European Journal of Cell Biology, 94(11), 513–521.
http://doi.org/10.1016/j.ejcb.2015.07.002
Tsika, E., Glauser, L., Moser, R., Fiser, A., Daniel, G., Sheerin, U.-M., … Moore, D. J.
(2014). Parkinson’s disease-linked mutations in VPS35 induce dopaminergic
neurodegeneration. Human Molecular Genetics, 23(17), 4621–4638.
http://doi.org/10.1093/hmg/ddu178

62
Tysnes, O. B., & Storstein, A. (2017). Epidemiology of Parkinson’s disease. Journal of
Neural Transmission, 124(8), 901–905. http://doi.org/10.1007/s00702-017-1686y
Vilariño-Güell, C., Wider, C., Ross, O. A., Dachsel, J. C., Kachergus, J. M., Lincoln, S.
J., … Farrer, M. J. (2011). VPS35 mutations in parkinson disease. American
Journal of Human Genetics, 89(1), 162–167.
http://doi.org/10.1016/j.ajhg.2011.06.001
Villa, N., Do, A., Hershey, J. W. B., & Fraser, C. S. (2013). Human eukaryotic initiation
factor 4G (eIF4G) protein binds to eIF3c, -d, and -e to promote mRNA
recruitment to the ribosome. The Journal of Biological Chemistry, 288(46),
32932–40. http://doi.org/10.1074/jbc.M113.517011
Vitting-Seerup, K., Porse, B. T., Sandelin, A., & Waage, J. (2014). spliceR: an R package
for classification of alternative splicing and prediction of coding potential from
RNA-seq data. BMC Bioinformatics, 15, 81. http://doi.org/10.1186/1471-210515-81
Wang, C.-L., Tang, F.-L., Peng, Y., Shen, C.-Y., Mei, L., & Xiong, W.-C. (2012). VPS35
regulates developing mouse hippocampal neuronal morphogenesis by promoting
retrograde trafficking of BACE1. Biology Open, 1(12), 1248–1257.
http://doi.org/10.1242/bio.20122451
Wang, C., Niu, M., Zhou, Z., Zheng, X., Zhang, L., Tian, Y., … Zhang, Y. (2016).
VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.
Neurobiology of Aging, 46, 22–31.
http://doi.org/10.1016/j.neurobiolaging.2016.05.016
Wang, D., Narula, N., Azzopardi, S., Smith, R. S., Nasar, A., Altorki, N. K., … Du, Y.-C.
N. (2016). Expression of the receptor for hyaluronic acid mediated motility
(RHAMM) is associated with poor prognosis and metastasis in non-small cell
lung carcinoma. Oncotarget, 7(26), 39957–39969.
http://doi.org/10.18632/oncotarget.9554

63
Wang, S., & Bellen, H. J. (2015). The retromer complex in development and disease.
Development, 142(14), 2392–2396. http://doi.org/10.1242/dev.123737
Wang, W., Wang, X., Fujioka, H., Hoppel, C., Whone, A. L., Caldwell, M. A., … Zhu,
X. (2016). Parkinson’s disease–associated mutant VPS35 causes mitochondrial
dysfunction by recycling DLP1 complexes. Nature Medicine, 22(1), 54–63.
http://doi.org/10.1038/nm.3983
Wen, L., Tang, F.-L., Hong, Y., Luo, S.-W., Wang, C.-L., He, W., … Xiong, W.-C.
(2011). VPS35 haploinsufficiency increases Alzheimer’s disease neuropathology.
The Journal of Cell Biology, 195(5), 765–779.
http://doi.org/10.1083/jcb.201105109
Williams-Gray, C. H., Mason, S. L., Evans, J. R., Foltynie, T., Brayne, C., Robbins, T.
W., & Barker, R. A. (2013). The CamPaIGN study of Parkinson’s disease: 10year outlook in an incident population-based cohort. Journal of Neurology,
Neurosurgery, and Psychiatry, 84(11), 1258–64. http://doi.org/10.1136/jnnp2013-305277
Williams, E. T., Glauser, L., Tsika, E., Jiang, H., Islam, S., & Moore, D. J. (2018). Parkin
mediates the ubiquitination of VPS35 and modulates retromer-dependent
endosomal sorting. Human Molecular Genetics.
http://doi.org/10.1093/hmg/ddy224
Winklhofer, K. F. (2014). Parkin and mitochondrial quality control: toward assembling
the puzzle. Trends in Cell Biology, 24(6), 332–41.
http://doi.org/10.1016/j.tcb.2014.01.001
Wooten, G. F., Currie, L. J., Bovbjerg, V. E., Lee, J. K., & Patrie, J. (2004). Are men at
greater risk for Parkinson’s disease than women? Journal of Neurology,
Neurosurgery, and Psychiatry, 75(4), 637–9.
http://doi.org/10.1136/JNNP.2003.020982
Yang, P.-T., Lorenowicz, M. J., Silhankova, M., Coudreuse, D. Y. M., Betist, M. C., &
Korswagen, H. C. (2008). Wnt Signaling Requires Retromer-Dependent

64
Recycling of MIG-14/Wntless in Wnt-Producing Cells. Developmental Cell,
14(1), 140–147. http://doi.org/10.1016/J.DEVCEL.2007.12.004
Yin, J., Liu, X., He, Q., Zhou, L., Yuan, Z., & Zhao, S. (2016). Vps35-dependent
recycling of Trem2 regulates microglial function. Traffic, 17(12), 1286–1296.
http://doi.org/10.1111/tra.12451
Yun, S. P., Kim, H., Ham, S., Kwon, S.-H., Lee, G. H., Shin, J.-H., … Lee, Y. (2017).
VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal
clearance of AIMP2. Cell Death & Disease, 8(4), e2741–e2741.
http://doi.org/10.1038/cddis.2017.157
Zavodszky, E., Seaman, M. N. J., Moreau, K., Jimenez-Sanchez, M., Breusegem, S. Y.,
Harbour, M. E., & Rubinsztein, D. C. (2014). Mutation in VPS35 associated with
Parkinson’s disease impairs WASH complex association and inhibits autophagy.
Nature Communications, 5(1), 3828. http://doi.org/10.1038/ncomms4828
Zhang, P., Wu, Y., Belenkaya, T. Y., & Lin, X. (2011). SNX3 controls Wingless/Wnt
secretion through regulating retromer-dependent recycling of Wntless. Cell
Research, 21(12), 1677–1690. http://doi.org/10.1038/cr.2011.167
Zhang, Q., Wu, X., Chen, P., Liu, L., Xin, N., Tian, Y., & Dillin, A. (2018). The
Mitochondrial Unfolded Protein Response Is Mediated Cell-Non-autonomously
by Retromer-Dependent Wnt Signaling. Cell, 174(4), 870–883.e17.
http://doi.org/10.1016/j.cell.2018.06.029
Zhang, Y., Chen, S., Xiao, Q., Cao, L., Liu, J., Rong, T.-Y., … Chen, S.-D. (2012).
Vacuolar protein sorting 35 Asp620Asn mutation is rare in the ethnic Chinese
population with Parkinson’s disease. Parkinsonism & Related Disorders, 18(5),
638–640. http://doi.org/10.1016/j.parkreldis.2012.02.011
Zimprich, A., Benet-Pagès, A., Struhal, W., Graf, E., Eck, S. H., Offman, M. N., …
Strom, T. M. (2011). A Mutation in VPS35, Encoding a Subunit of the Retromer
Complex, Causes Late-Onset Parkinson Disease. The American Journal of
Human Genetics, 89(1), 168–175. http://doi.org/10.1016/j.ajhg.2011.06.008

65

APPENDIX A

66
Nestin-Positive/Sox2-Negative Cells Mediate Adult Neurogenesis of Nigral
Dopaminergic Neurons in Mice
Citation: Albright, J. E., Stojkovska, I., Rahman, A. A., Brown, C. J., & Morrison, B. E.
(2016). Nestin-positive/SOX2-negative cells mediate adult neurogenesis of nigral
dopaminergic neurons in mice. Neuroscience Letters, 615, 50–54.
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Introduction
Parkinson’s disease (PD) is the most common motor disorder and the second most
prevalent neurodegenerative disease. PD motor dysfunction (rigidity, tremor,
bradykinesia, and postural instability) results from loss of dopaminergic (DA) neurons in
the substantia nigra (SN). However, a basic understanding of the mechanism for DA
neuron loss remains elusive. Consequently, only symptomatic treatments exist for PD and
none that address the underlying neurodegeneration. Determining whether DA neurons
are replenished in the adult SN is fundamental to understanding the loss of these neurons
during PD. One possibility is that suppression of adult DA neurogenesis could be a
driving force toward PD. Additionally, exploiting endogenous neurogenesis could offer
potential avenues for therapy as well as better inform stem cell transplantation efforts.
Deficiencies in the process of adult neurogenesis have been strongly associated
with Alzheimer’s disease (AD), a neurodegenerative disorder sharing many
epidemiological features with PD. Hippocampal neurons responsible for memory
processing are preferentially lost in AD and evidence suggests this may be due, in part, to
decreased neurogenesis (reviewed in [1]). Hippocampal adult neurogenesis occurs at a
high rate throughout life but appears to decrease sharply in human AD as well as mouse
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models of the disease. Interventions that promote adult neurogenesis improve preclinical
model outcomes for histopathology as well as functionality. Neurogenesis of
hippocampal neurons in adult humans and rodents begin from stem cell (SC) populations
residing in the subgranular zone (SGZ) of the dentate gyrus. SC populations are
relatively less differentiated and possess replicative capacity. Therefore, these cells can
regenerate the SC pool as well as contribute progeny that can differentiate into neuronal
precursor cells (NPCs) that are post-mitotic and committed to neuronal fates.
In addition to hippocampal neurons, olfactory neurons are replenished throughout
the life of primates and rodents. SCs responsible for this process reside in the
subventricular zone (SVZ). Once born, NPCs migrate a considerable distance to the
olfactory bulb before integration and final differentiation into functional neurons.
Currently, the SGZ and SVZ are the only known locations for SC generation in the adult
mammalian brain. However, whether NPC pools reside elsewhere or transdifferentiation
to NPCs from existing cell types occur remains to be determined.
The evidence for a contribution of adult neurogenesis to PD is inconclusive.
Reduced proliferation of SVZ cells has been reported in human PD [2,3]. Additionally, a
number of studies have reported that wide-spread overexpression of a protein known to
be a monogenic cause of rare forms of PD, alpha-synuclein (WT, A53T, E46K, and
A30P), in mice results in inhibition of neurogenesis in the SGZ and SVZ [4-8].
Moreover, transgenic mouse overexpression of PD-causing mutations in leucine-rich
repeat kinase 2 (LRKK2) hinder proliferation and survival of SCs in the SVZ and SGZ
[9]. However, a major caveat is that none of these mouse models induce DA neuron loss
in the SN so the relevance to DA neurogenesis or even PD is debated. Administering the
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PD model neurotoxins 6-OHDA or MPTP in rats or mice, respectively, does target DA
neurons and inhibition of SC generation in the SVZ has been reported [2,10,11].
Conversely, other groups have reported increased neurogenesis following MPTP
treatment [12]. In any event, the DA neuron loss in these models is rapid, easily
achieving 80-100% loss within two weeks. Such a speedy loss does not mirror human
progressive PD and cannot be explained by suppression of neurogenesis making
connections between PD and this process using these neurotoxins dubious.
Attempts have been made to monitor adult DA neurogenesis in the SN directly
using various cell lineage tracing methods with conflicting results [13-15]. Lack of
compelling evidence for DA neurogenesis has reinforced the prevailing notion that the
presence of a toxic stimulus or trophic factor withdrawal induces mature DA neurons to
undergo death in a slow and progressive manner. Therefore, while still controversial, the
predominate viewpoint is that stem cell replacement of adult DA neurons in the SN does
not occur at appreciable levels [13]. The most prevalent method of DA neuron lineage
tracing utilizes DNA incorporation of the thymidine analog bromodeoxyuridine (Brd-U)
or similar reagent to monitor for cell division of SCs. This method is problematic for a
number of reasons. Firstly, Brd-U is quite toxic to the organism and to dividing cells.
Secondly, Brd-U can yield false-positive results for cells undergoing DNA repair.
Additionally, these regimens of Brd-U use are adopted from studies focused in regions of
the brain exhibiting high levels of neurogenesis such as the hippocampus. Moreover, use
of this chemical requires double-immunolabeling for the DA neuron marker tyrosine
hydroxylase (TH) and Brd-U. Resolution of double-positive cells requires great care
using confocal microscopy and issues have been reported [15]. This method is also not
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readily amenable to large sample numbers. Another common method of lineage tracing is
by injection of retrovirus to permanently label SCs and NPCs. However, this requires
knowledge of the precursor cell location which is currently unknown. The aim of this
study was to overcome these limitations by employing a novel system that utilizes a drug
that could be administered for 6-8 weeks without severe health complications, extends
the post-labeling duration, and allows for accurate quantitation of DA neurons in the SN
of mice by single-labeling.
Methods
All husbandry and study procedures involving mice were performed in
accordance with Boise Veterans Affairs Medical Center Institutional Animal Care and
Use Committee guidelines. Thlox mice [16] were kindly provided by Drs. Richard
Palmiter and Martin Darvas at The University of Washington. The nestin-CREERT2 [17]
and Sox2-CREERT2 [18] mouse lines were obtained from The Jackson Laboratory. Mice
were fed ad libitum and maintained on 12hr light/dark cycles. For tamoxifen treatment,
three-month-old mice were provided 400mg/kg tamoxifen citrate chow (Envigo) as sole
food source for 6 weeks. Mice were then placed back on standard rodent chow for the
remainder of the study.
For Immunohistochemistry (IHC), mice (n = 6 per group) were anesthetized with
5% isoflurane and transcardially perfused with 10mL 0.1M phosphate buffer (PB) (pH
7.2) with 1mM EDTA followed by 10mL 4% paraformaldehyde (PFA) in PB. Brains
were harvested and then fixed in 4% PFA for 24h at 4°C. Next, brains were cryoprotected
in 30% sucrose/PB at 4°C until sunk. The brains were then frozen in OCT media and a
Leica CM1950 cryostat used to cut 35 µm sections. Free-floating IHC was performed
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with three PB washes between each step. Endogenous peroxidase activity was removed
with H2O2 (3%) and methanol (10%) for 30min followed by blocking and
permeabilization with 0.5% bovine serum albumin/0.2% triton X100/PB solution for 1h.
To label DA neurons a primary antibody against tyrosine hydroxylase (EMD Millipore;
AB152) (1:2000 dilution) was used overnight at 4°C. A secondary antibody conjugated to
biotin (Jackson Immuno Research) (1:500 dilution) was then applied for 1h at room
temperature followed by ABC staining (Vector Labs) (A and B solutions at 1:100
dilutions) for 1h. DA neurons were visualized using 3,3' diaminobenzidine (DAB)
(Sigma Aldrich) substrate addition at 1mg/mL (pH 7.2) and allowed to develop for 4 min.
The reaction was stopped in ddH2O, sections placed on slides, dried, and coverslips
mounted using Vectamount.
All DA neuron somas in the SN for all SN-containing sections in the right
hemisphere (average of 38.6 sections per hemisphere) were counted using bright field
microscopy. The left hemisphere was punctured with a 30-gauge needle at the time of
cryosectioning to identify hemispheres. To correct for bisected DA neuron somas
appearing in adjacent sections, the Abercrombie factor was determined and applied to
counts [19].
Data is presented as mean ± SEM for groups. Statistical significance (p < 0.05)
between groups was determined using multiple-way ANOVA followed by a post hoc
Tukey’s test using GraphPad Prism 6 software.
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Results

Figure A1.

Genetic model to assess adult DA neurogenesis.

Tamoxifen (Tam) treatment activates CRE activity in nestin or Sox2-expressing cells
resulting in Th gene silencing.

A genetic approach was developed to remove the DA neuron marker tyrosine
hydroxylase (TH) from precursor cells in adult mice (Fig. A1). Consequently, if DA
neurons were replenished in adult mice, there should be a gradual loss of TH positive
neurons in the SN over time following removal of the Th gene from precursor cells.
Tamoxifen-inducible Th excision was chosen for this drug’s ability to readily cross the
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blood-brain barrier and good tolerability. To target NPCs for Th excision, nestin and Sox2
promoters were selected to drive the expression of a tamoxifen-inducible CRE
recombinase (CREERT2) in SCs and/or NPCs. Nestin and Sox2 are two of the most welldescribed neural progenitor markers and are not expressed in mature neurons making
them good initial candidates to target DA neuron precursors. Both nestin-CREERT2 [17]
and Sox2-CREERT2 [18] mouse lines were crossed with transgenic mice possessing the
endogenous Th gene engineered with loxP sites flanking exon 1 [16] thereby allowing for
the excision and silencing of Th in the presence of CRE activity. Three-month-old double
or single (control) transgenic mice (nestinCRE-ERT2:Thlox/lox, Sox2CRE-ERT2:Thlox/lox, or
Thlox/lox) were treated with or without tamoxifen-laden chow for six weeks (Fig. A2A).
Six months following initiation of tamoxifen treatment brains were harvested and DA
neurons in the SN counted. Remarkably, tamoxifen treated nestinCRE-ERT2:Thlox/lox mice
exhibited significantly fewer TH+ neurons in the SN than controls (Fig. A2B, Fig AS1).
In addition, no reduction in TH+ cells was observed in the SN of untreated nestinCREERT2

:Thlox/lox mice or tamoxifen-treated Sox2CRE-ERT2:Thlox/lox or Thlox/lox mice indicating

that the loss in TH signal was due to Th gene excision and not the result of non-specific
downregulation of Th expression by tamoxifen or the presence of the CRE transgene.
Therefore, this result indicates that a nestin-positive population of precursors replenishes
adult DA neurons in mice. However, it was surprising to find that Sox2CRE-ERT2:Thlox/lox
mice showed no TH+ cell loss given that Sox2 has been widely reported to be a
ubiquitous neural SC marker [20,21].
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Figure A2.

Adult DA neurogenesis by Nestin positive NPCs.

Six-week treatment with tamoxifen (Tam) citrate chow (400mg/kg chow) was used to
activate CREERT2 activity in 3-month-old transgenic mice (A). NestinCREERT2:Thlox/lox mice showed decreased DA neurons in the SN following Tam treatment
(B). DA neurons in the SN were visualized by IHC (DAB). All sections containing SN
from the right hemisphere were counted and neuron totals were corrected using the
Abercrombie factor. Multiple-way ANOVA was performed followed by posthoc Tukey’s
test (6 mice per group; error bars = SEM; * = p<0.05; ns = not significant).
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Discussion
This study provides compelling evidence for DA neurogenesis in the SN of adult
mice by utilizing a novel cell lineage tracing model. Discovery of a nestin+ pool of DA
progenitor cells will empower future studies to focus on the process of adult neurogenesis
for DA neurons as well as enable locating these cells within the mammalian brain.
Interestingly, this study found that Sox2 was not expressed in progenitors that gave rise
to DA neurons in the adult SN. Sox2 expression is largely restricted to neural SCs, being
turned down following cell cycle exit [22]. Additionally, Sox2 expression is closely
linked to SC function, being one of four transcription factors (Oct3/4, Sox2, c-Myc, and
Klf4) whose overexpression in concert can induce adult somatic cells to become embryolike SCs [23]. Nestin is an intermediate filament protein expressed by SCs and NPCs in
vivo and in vitro and may persist for a longer period of time than Sox2 expression
(reviewed in [24]). Thus, targeting nestin-expressing cells will affect SOX2+ SCs in
addition to a more differentiated progenitor population. Taken together, this may suggest
that SOX2- cells giving rise to DA neurons in the adult SN exhibit greater differentiation
and are not renewed by SCs. The implication would be that there is a limited supply of
DA neuron progenitors available for adult neurogenesis. Therefore, depletion of this
progenitor pool by normal turnover or by deleterious factors would result in an eventual
loss of mature DA neurons. Another possibility is that SCs are not needed due to
transdifferentiation of progenitors from another cell type. Investigation of additional
neural SC and NPC markers by cell lineage tracing in vivo might address this.
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The cause of DA neuron loss in PD has remained a mystery despite several
decades of intense investigation. Over this time, considerable effort has been placed in
identifying factors that induce death of mature DA neurons in vitro and in vivo. However,
if DA neurogenesis is a natural ongoing homeostatic mechanism in the brain as evidence
presented here suggests, inhibition of this process could be responsible, at least in part,
for the progressive loss of DA neurons observed in PD. Reports of heightened sensitivity
for SC and NPC populations in the adult brain to enhanced inflammatory response and
other toxic stimuli support this notion [25-27]. Interestingly, the rate for DA neuron loss
in the SN using a purely inflammatory model of PD reported by two groups mirrors TH+
cell loss by nestin-mediated Th excision shown in Fig. 2B. Extrapolating for single brain
hemispheres, data presented by Frank-Cannon et al. [28] and Morrison et al. [29] indicate
an approximate rate of 14.3 and 12.3 DA neuron loss/day, respectively. If the total TH+
cell loss in the SN observed in Fig. 2B is divided by the tamoxifen treatment duration of
six weeks, a rate of 13.9 ± 1.2 is yielded. This is an intriguing correlation that would also
suggest that the enhanced inflammatory model might mediate neurodegeneration by
impeding adult neurogenesis of DA neurons. Future studies are warranted to further
substantiate this association.
Findings from this study may direct stem cell replacement therapy for PD.
Growth of stem cell research in the late 1980’s generated great interest for use of this
technology as a potential PD treatment. However, clinical trials using fetal stem cells to
replace lost DA neurons have yielded promising but variable results [30,31]. The
variability was believed to result from inconsistent source stem cells. Thorough
characterization of neural stem cells in vivo may allow for the development of
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appropriate and consistent cell types for therapy. Therefore, identification and
characterization of the newly discovered nestin+/Sox2- DA neuron precursor population
will provide a foundation for these investigations.
In conclusion, this study reveals the existence of a nestin+/SOX2- DA progenitor
pool that replenishes mature DA neurons in the adult mouse SN. This finding has broad
implications for brain biology and PD pathology and serves as a basis for future
investigation of these important cells.
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Figure AS1. IHC detection of TH+ cells in the SN.
Transgenic mice were sacrificed six months following treatment with or without
tamoxifen (Tam)-laden chow. IHC (DAB) was then performed to quantify DA neurons in
the SN using a TH antibody. Representative images from similar levels of the SN are
shown. Note that differences in TH+ cell density are not readily apparent from
comparison of single sections and require compiling DA neuron counts across all sections
of each mouse.
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Nigral Dopaminergic Neuron Replenishment in Adult Mice Through Ve-CadherinExpressing Neural Progenitor Cells
Citation: Rahman, A. A., Lai, N. K., Albright, J. E., Urquhart, P. E., Webb, A. R., &
Morrison, B. E. (2017). Nigral dopaminergic neuron replenishment in adult mice through
VE-cadherin-expressing neural progenitor cells. Neural Regeneration Research, 12(11),
1865–1869. http://doi.org/10.4103/1673-5374.219050
Abstract
The function of dopaminergic neurons in the substantia nigra is of central
importance to the coordination of movement by the brain’s basal ganglia circuitry. This is
evidenced by the loss of these neurons, resulting in the cardinal motor deficits associated
with Parkinson’s disease. In order to fully understand the physiology of these key
neurons and to craft potential therapies for their loss, it essential to determine if and how
dopaminergic neurons are replenished in the adult brain. Recent work has presented
evidence for adult neurogenesis of these neurons by Nestin+/Sox2- neural progenitor
cells. We sought to further validate this finding and explore a potential atypical origin for
these progenitor cells. Since neural progenitor cells have a proximal association with the
vasculature of the brain and the subsets of endothelial cells are Nestin+, we hypothesized
that dopaminergic neural progenitor cells might share a common cell lineage. Therefore,
we employed a VE-cadherin promoter-driven CREERT2:THlox/lox transgenic mouse line to
ablate the tyrosine hydroxylase gene function from endothelial cells in adult animals.
After six months, but not three months, following the genetic blockade of tyrosine
hydroxylase expression in VE-cadherin+ cells, we observed a significant reduction in
tyrosine hydroxylase+ neurons in the substantia nigra. The results from this genetic
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lineage tracing study suggest that dopaminergic neurons are replenished in adult mice by
a VE-cadherin+ progenitor cell population potentially arising from an endothelial cell
lineage.
Introduction
The existence of adult neurogenesis for dopaminergic (DA) neurons is
controversial. However, a major limitation of previous studies is their reliance upon
nucleotide analog, such as bromodeoxyuridine (BrdU), incorporation to identify
replicating neurons (Kay and Blum, 2000; Zhao et al., 2003; Frielingsdorf et al., 2004;
Aponso et al., 2008). This approach presumes that DA neurons in adult animals are
generated in a replication-dependent manner from neural progenitor cells (NPCs). Recent
studies have demonstrated in multiple animal systems, including mice, that quiescent,
non-replicative neurogenesis occurs for some neural populations within the adult brain
(Nishimura et al., 2011; Barbosa et al., 2015; Fuentealba et al., 2015). Additionally,
previous studies that have focused on DA adult neurogenesis employed relatively short
labeling and post-labeling periods, thereby decreasing the ability to detect the slow
regeneration rates (Zhao et al., 2003; Frielingsdorf et al., 2004; Arias-Carrión et al.,
2009). To avoid these potential pitfalls, we have established a transgenic mouse system
that utilizes genetic cell lineage tracing observed over a six-month period.
Neurons are believed to arise from ectodermal tissue during embryonic
development, while endothelial cells likely arise from the mesoderm. However, a strong
connection exists among vascular physiology, NPCs, and Parkinson’s disease (PD).
NPCs in the adult brain have been reported to reside and differentiate in close association
with capillaries, suggesting an intimate relationship with endothelial cells (Siegenthaler
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and Pleasure, 2010). One unexplored possibility, supported by mounting evidence, is that
specialized endothelial cells give rise to NPCs. For example, a number of factors
associated with endothelial physiology (e.g., VEGF and endothelin) have robustly
influenced outcomes in pre-clinical models of neurodegenerative disease (Wang et al.,
2007; Kirby et al., 2015). Remarkably, similar to DA neurons, subsets of endothelial cells
have been demonstrated to produce and respond to dopamine (Basu et al., 2001;
Sorriento et al., 2012). In addition, when co-cultured with endothelial cells, it has been
reported that mouse NPCs differentiate into endothelial cells (~6% rate) capable of
forming capillary networks, which blurs the lines between these cell types (Wurmser et
al., 2004).
NPCs express a number of endothelial cell markers and share common niches
within the brain. For instance, Pramel7 was recently identified as a marker and mediator
for a pre-implantation embryonic stem cell pluripotency ground state that has limited
replicative self-renewal capacity (Graf et al., 2017). In situ RNA hybridization data on
adult mouse brains available from the Allen Institute for Brain Science indicates that
Pramel7 is expressed in the meninges, most likely in the endothelial cells (Lein et al.,
2007). Moreover, the greatest concentration of positive signal arises from the meninges
immediately ventral to the substantia nigra. This is particularly interesting given that
Bifari et al. recently reported that quiescent NPCs generated during embryogenesis
migrate from the meninges to differentiate into cortical neurons without replication in
adult mice (Bifari et al., 2016). Previous work has also shown that DA neurons in the
substantia nigra (SN) express IL-13RA1, a histological marker for endothelial cells
(Morrison et al., 2012). Additionally, the discovery of a Nestin+/Sox2- DA NPC
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population in adult mice reported by Albright and colleagues may indicate an atypical
origin for these cells since Sox2 is broadly reported as a canonical marker for NPCs
(Albright et al., 2016). Nestin+/Sox2- cells (NeuN-; non-neural) were also described by
Hendrickson et al. and reside in a satellite position directly neighboring mature neurons
in the adult rat brain. This suggests that these cells may represent previously
uncharacterized NPCs (Hendrickson et al., 2011). In addition, Nestin+ endothelial cells
are found throughout the body (Suzuki et al., 2010). Whether there is a connection
between Nestin+/Sox2- DA NPCs and Nestin+ endothelial cells, Nestin+ endothelial
precursor cells, or Nestin+ mesenchymal stem cells (Pacini and Petrini, 2014) that are
known to regulate endothelial progenitor cell differentiation and which might directly
transdifferentiate into endothelial cells (Xie et al., 2015), could be fundamental toward
understanding DA neurogenesis. We therefore seek to determine if adult DA NPCs are
derived from an endothelial cell lineage.
Materials and Methods
Experimental Animals
Procedures and husbandry for study animals were performed under Boise State
University and Boise Veterans Affairs Medical Center Institutional Animal Care and Use
Committee guidelines and in accordance with the Guide for the Care and Use of
Laboratory Animals (National Research Council (US) Committee for the Update of the
Guide for the Care and Use of Laboratory Animals, 2011). The THlox mouse line (Jackson
et al., 2012) used in this study was a kind gift from Dr. Martin Darvas and Dr. Richard
Palmiterat (The University of Washington). The VE-cadherin-CREERT2 mice were
generously provided by Dr. Luisa Iruela-Arispe (The University of California, Los
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Angeles). During the course of this study, mice were provided food ad libitum and
housed with 12-hour day-night cycles. Tamoxifen treatment was administered to threemonth-old mice via standard rodent chow infused with 400 mg/kg tamoxifen citrate
(Envigo; TD.130860), which was provided as the lone food source for a duration of six
weeks. Following treatment, mice were returned to a standard chow diet.
Tissue processing and immunohistochemistry
Mice were anesthetized by isoflurane inhalation and transcardially perfused with a
50 mL phosphate buffer (PB; pH 7.2) containing heparin sodium salt (20 units/mL)
followed by 50 mL of a 4% paraformaldehyde (PFA) in PB solution. Mouse brains were
collected and placed in 4% PFA/PB overnight at 4°C. The following day, the brains were
placed in 30% sucrose/PB at 4°C until they sunk (~72 hours). Tissue was then rapidly
frozen in OCT and stored at -80°C until immunohistochemistry (IHC) was performed.
For IHC, OCT-embedded brains were equilibrated to a cryostat (Leica CM1950)
at -20°C overnight. Sections were then cut at a thickness of 35 µm, placed into 12 well
plates containing PB, and processed by free-floating IHC. Endogenous HRP activity was
quenched with a 3% H2O2/10% methanol/PB solution incubated for 15 min at room
temperature. Sections were then blocked and permeabilized with 0.5% BSA/0.25%
Triton X100/PB. A TH antibody (Millipore; AB152) was used at 1:2,000 (in 0.5%
BSA/PB), 4°C overnight. A biotinylated secondary antibody (Jackson Immuno Research;
BA-1000) solution (1:500) was then added and incubated at room temperature for 1 h.
Next, streptavidin-HRP was added according to manufacturer instructions (Vector Labs;
PK-6200). Wash steps were performed using PB. TH labeling was visualized using 50
mg/mL 3,3'-Diaminobenzidine tetrahydrochloride hydrate (DAB; VWR cat # AAJ62216-
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09) in PB. Sections were dried overnight, placed on slides, and then coverslips were
mounted with Vectamount (Vector Labs; H-5000).
Quantification of DA neurons in the SN
DAB-labeled DA neurons were visualized with bright-field microscopy. For
counting purposes, the left hemisphere was marked by piercing with a 20-gauge needle
prior to sectioning the SN. Each tissue section containing SN from the right brain
hemisphere was quantified following IHC. The SN was represented in an average of 38.9
sections/hemisphere across all samples. DA neuron counts included the substantia nigra
pars compacta and excluded TH+ neurons located in the adjoining ventral tegmental area.
Isolation of endothelial cells and assessment of TH excision
Primary mouse endothelial cells were obtained by magnetic-activated cell sorting
(MACS) as previously described (Shi et al., 1999). Briefly, 6-month-old mice were
sacrificed, one liver lobe harvested, and placed in DMEM on ice. Livers were then
minced using sterile razor blades. Each diced liver sample was then transferred to a tube
containing 100mg of collagenase Type I (Rockland Immunochemical; MB-118-0100) in
25 mL of HBSS (+Calcium, +Magnesium, +1%BSA). Tubes were incubated with
occasional mixing in a 37°C water bath for 60 minutes. Samples were then filtered
through a 70µm sterile cell strainer and centrifuged at 300Xg for 5 min at 4°C.
Supernatants were discarded and pellets washed once with 0.1% BSA/PBS and
centrifuged at 300 Xg for 5 min at 4°C. Supernatants were aspirated and pellets
resuspended in 0.5% BSA/PBS with 2mM EDTA. MACS was performed according to
the manufacturers (MiltenyiBiotec) protocol using positive selection with CD31
microbeads and MS columns. Following endothelial cell isolation, DNA was extracted
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using a mouse tissue DNA extraction kit (Biopioneer; MAQ-1). PCR was performed
using the following primers: TAGGGAGATGCCAAAGGCTA;
CAGGACCCAACAGAAGCATT. Thermocycling was done using the following
parameters: annealing temperature = 62C, 30 seconds; extension time = 30 seconds;
cycles = 35.PCR products were labeled with SYBR safe and resolved on a 1.5% agarose
gel.
Statistical analysis
DA neuron counts were analyzed for significance (p < 0.05) among groups using
a multiple-way ANOVA in conjunction with a post hoc Tukey’s test using Graphpad
Prism 6 software. Means are shown and the standard error of the mean is represented by
error bars.
Results
DA NPCs express VE-cadherin
To test whether DA neurons arise from an endothelial cell lineage in adult
animals, we generated the transgenic mouse shown in Figure B1 where, in effect, the TH
gene is being utilized as a genetic cell lineage tracing marker.
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Figure B1.

Inducible transgenic mouse model for adult DA neurogenesis
assessment.

Three-month-old mice expressing CRE-ERT2 under the control of a VE-cadherin
promoter were given tamoxifen (Tam)-laden chow, resulting in excision and silencing of
the loxP-containing TH gene (homozygous) in VE-cadherin+ cells.

A Vascular Endothelial Cadherin promoter was used to drive expression of a
tamoxifen-activatable CRE recombinase (VE-cadherin CREERT2) in endothelial cells
(Monvoisin et al., 2006). Upon activation of CRE activity by tamoxifen treatment in adult
mice (three months of age), the tyrosine hydroxylase (TH)gene was silenced by excision
in VE-cadherin positive cells. Six months after initiation of a six-week tamoxifen
treatment, the mice were assessed for loss of nigral DA (TH+) neurons (Figure B2A).
Interestingly, VE-cadherinCRE-ERT2 mice receiving tamoxifen displayed a reduction in DA
neurons within the SN (Figure B2C). To verify whether this loss resulted from TH
excision in DA progenitors or from existing mature DA neurons, we assessed DA
neurons in a cohort of VE-cadherin promoter-driven CREERT2:THlox/lox mice three months
after tamoxifen administration (Figure B2B). We observed no loss in nigral DA neurons
in this group, indicating that TH excision occurred in cells other than mature DA neurons.
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In addition, we confirmed successful TH excision from endothelial cells isolated from
tamoxifen treated VE-cadherin promoter-driven CREERT2:THlox/lox mice(Figure 3).

Figure B2.

Adult nigral DA neurogenesis by VE-cadherin+ progenitor cells.

Tamoxifen (Tam) citrate-laden chow (400mg/kg food pellet) was fed ad libitum to threemonth-old transgenic mice (A). Brains were harvested, IHC performed for TH
immunoreactivity, and DA neurons quantified at 13 and 26 weeks following Tam
administration. No difference was observed among groups at three months following
Tam treatment (B). However, at 6 months post-treatment, VE-cadherinCRE-ERT2:THlox/lox
mice showed significantly reduced DA neurons in the SN compared with control groups
(C). Every tissue section in the right hemisphere containing SN was counted. Statistical
analysis was performed using a multiple-way ANOVA in conjunction with a post hoc
Tukey’s test (group size = 6 mice; error bars = SEM; * = p<0.05 compared across all
other groups). Nigral DA neurons were observed by IHC using a TH antibody (DAB).
Representative images are shown (scale bar = 500 µm) (D).
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Figure B3.

Endothelial TH excision from VE-cadherincreERT2: THlox/ox transgenic
mouse line treated with Tamoxifen.

Endothelial cells were isolated by MACS from livers harvested from untreated or TAM
treated (400 mg/kg, 6 weeks chow) mice. DNA was then extracted and PCR performed to
verify excision of TH in endothelial cells.
Discussion
Determining whether DA neurons undergo adult neurogenesis is of central
importance to understanding fundamental brain physiology as well as developing
potential therapies to combat their loss. Our current study has presented evidence in favor
of dopaminergic neuron regeneration in adult mice through VE-cadherin-expressing
NPCs. This finding builds upon previous work demonstrating that Nestin+/Sox2- NPCs
in the adult mouse brain regenerate nigral DA neurons in a slow, progressive manner
(Albright et al., 2016). These results are also consistent with the possibility of an
endothelial cell-derived DA NPC population in adult mice.
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The data presented here might also explain the mounting evidence linking DA
neuron and endothelial physiology. In addition to the ability to produce and respond to
dopamine, endothelial cells exhibit acute sensitivity to inflammatory response and
oxidative stress (Pober and Sessa, 2007). Interestingly, oxidative stress has been shown to
cause mesenchymal transdifferentiation of endothelial cells in vivo, providing further
support for the plasticity of endothelial cells (Montorfano et al., 2014). If DA neurons
share a close lineage with endothelial cells, our findings offer an explanation for the
unique sensitivity of DA neurons toward oxidative and inflammatory response-based
systemic insults. For example, peripheral administration of the potent oxidizing agent
paraquat has been reported to cause the specific loss of nigrostriatal DA neurons
(McCormack et al., 2002). In addition, systemic (intraperitoneal) administration of
bacterial lipopolysaccharide twice weekly for six months results in chronic inflammatory
response and in a selective, slow, and progressive loss of DA neurons in the SN (Qin et
al., 2007; Frank-Cannon et al., 2008). Furthermore, the neurotoxic effect of MPTP on DA
neurons can be completely halted with anti-inflammatory therapy (Aubin et al., 1998;
Nomura et al., 2011). Similarly, NSAID use, particularly ibuprofen, has been correlated
with a reduced incidence for PD suggesting the presence of an inflammatory instigator in
human disease that targets these neurons (Chen et al., 2003; Gao et al., 2011). Therefore,
a growing body of data indicates that DA neurons experience heightened sensitivity,
compared with other neural populations, to insults that could, in part, be explained by
physiology shared with endothelial cells.
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Recent work by multiple groups in diverse systems has revealed the existence of
replication-independent adult neurogenesis (Nishimura et al., 2011; Barbosa et al., 2015;
Fuentealba et al., 2015; Bifari et al., 2016). These studies have shown that quiescent
NPCs, produced and expanded during embryogenesis, directly differentiate into neurons
as needed in the adult animal. If a similar mechanism is responsible for the generation of
DA neurons in adults, it would provide an explanation for an inability to detect DA
neurogenesis using assays that rely upon nucleotide analog incorporation (e.g., Brd-U)
(Frielingsdorf et al., 2004). Additionally, previous studies employing a nucleotide
labeling strategy have utilized a relatively short post-labeling period before brain
harvesting, ranging from 8 hours to 6 weeks (Kay and Blum, 2000; Zhao et al., 2003;
Frielingsdorf et al., 2004; Aponso et al., 2008). This approach could dramatically limit
the ability to detect DA neurogenesis if, as our results suggest, this process occurs at a
very slow rate and is, using our method, undetectable at three months post-labeling. If a
replicative population of DA NPCs exists, then it will be essential to allow enough time
for differentiation into a TH+ neuron to occur before assessment. Therefore, further
investigations using alternative strategies, like the one demonstrated here, are warranted
to identify the precise source of DA NPCs and characterize this regenerative process so
that it can be harnessed for therapeutic benefit.
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